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ABSTRACT

The Use of Reverse Genetics to Clone and Rescue Infectious, Recombinant
Human Parainfluenza Type 3 Viruses

by

Jason P. Roth, Doctor of Philosophy
Utah State University, 2009

Major Professor: Dr. Dale L. Barnard
Department: Animal, Dairy, and Veterinary Sciences

Reverse genetics is a discipline that involves the use of genetic manipulation and
modification to study an organism’s altered phenotype. In this study, infectious
recombinant viruses were rescued from altered cDNA clones encoding the antigenome of
human parainfluenza virus type 3 and the resulting phenotypes were examined. In one
clone, the gene for the enhanced green fluorescent protein was inserted into the virus
antigenome to be expressed during viral replication, resulting in infected cells emitting
green fluorescence. Viral titers, mRNA replication, and genomic replication for the virus
expressing the enhanced green fluorescent protein were reduced when compared to the
human parainfluenza virus type 3 wild-type strain. In addition, the sensitivity of the virus
expressing the enhanced green fluorescent protein to antiviral compounds is increased
when compared to the wild-type strain, which may lead to the identification of false
positive antiviral compounds. An assay that measures the enhanced green fluorescent
protein as a direct indicator of virus replication can be shortened to 3 days in duration and
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is a more robust assay compared to assays that measure cellular viability. In other clones,
mutations were introduced into the phosphoprotein gene to eliminate the expression of
the D domain of the PD protein in order to understand its function. The titers of two
recombinant knockout viruses that are deficient in the expression of the D domain are
reduced when compared to the wild-type strain in both MA-104 and A549 cells. In
MA-104 cells, viral mRNA transcription and genomic replication of the two knockout
viruses are reduced when compared to the wild-type strain. In A549 cells, cellular
expression and secretion of antiviral cytokines infected with the two knockout viruses are
either reduced or remain unchanged when compared to the wild-type strain. These
results suggest that the D domain may play a role in viral RNA synthesis and not in
counteracting the host cell’s antiviral response. The results of these studies shed light on
the influence an additional gene has on viral replication and possible functions of the D
domain.
(166 pages)
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CHAPTER 1
INTRODUCTION

Reverse genetics is a discipline that involves the use of genetic manipulation and
modification to study an organism’s altered phenotype. Reverse genetics has been
particularly useful when studying viruses because of the ease of manipulation, due to
their relatively small genomes, and their short and quick replication rates leading to rapid
phenotypic expression. To study RNA viruses by reverse genetics, their complete
genomes must first be reverse transcribed into a cDNA clone, which can then be
manipulated in many ways. To rescue or create an infectious, recombinant RNA virus,
the cDNA clone must be converted back into RNA. Negative-sense RNA viruses are
problematic because their viral RNA lacks the signals recognized by eukaryotic host cells
for transcription and translation. Therefore, no viral positive or negative-sense genomic
RNA strands, viral mRNA strands, or viral proteins are produced from transfected naked
negative-sense viral genomic RNA alone to induce an infection. To circumvent these
problems, viral proteins necessary for viral mRNA transcription and genomic replication,
which are supplied by the virus during normal replication, need to be present during the
artificial rescue of an RNA virus from a cDNA clone. Once an infectious, negative-sense
RNA virus has been rescued, the phenotype of the recombinant virus can be studied.
Human parainfluenza virus type 3 (HPIV-3), a non-segmented negative-sense
RNA virus, was chosen for this project. HPIV-3 has a genome length of 15,462 nt and
encodes eight known proteins, nucleocapsid protein (NP), phosphoprotein (P), C protein,
PD protein, matrix protein (M), fusion protein (F), hemagglutinin-neuraminidase protein
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(HN), and large protein (L). In the middle of the P gene, an editing site exists where the
viral polymerase, L, stops and stutters, adding non-templated guanosine (G) residues.
This leads to the expression of three fusion proteins with similar N-terminal ends and
differing C-terminal ends; P, PD, the putative W protein, and perhaps a theoretical V
protein. The NP, P and L proteins, which are necessary for all aspects of viral RNA
synthesis, were present for the successful rescue of the recombinant HPIV-3 cDNA
clones used in the present study.
In the current study, reverse genetics was used to construct an infectious,
recombinant (r)HPIV3 clone, which contained three genetic markers to distinguish the
recombinant viruses from the wild-type (WT) virus and served as the backbone for all
other recombinant viruses. In the first phase of this study, the gene for the enhanced
green fluorescent protein (EGFP) was inserted into the rHPIV3 antigenome
(rHPIV3-EGFP) and used as a marker for active viral replication. The hypothesis for this
phase of the research was that the expression of the additional gene from the viral
genome would not attenuate the rHPIV3-EGFP virus; the replication rates and antiviral
sensitivity profiles would be similar to the rHPIV3 and HPIV-3 WT viruses. The
following aims were used to test the hypothesis:
1. To detect any differences in the replication rates of the three viruses, HPIV-3 WT,
rHPIV-3, and rHPIV3-EGFP, viral titers and replication curves are obtained for each
virus.
2. To detect any differences in viral mRNA transcription and viral genomic replication
rates between HPIV-3 WT and rHPIV3-EGFP, each process was measured by
quantitative reverse transcription polymerase chain reaction (QRT-PCR).
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3. To detect any differences in antiviral sensitivity and cytopathic effect (CPE) between
HPIV-3 WT and rHPIV3-EGFP, the sensitivity of each virus to antiviral compounds
and CPE was measured by neutral red (NR) absorption.
4. To investigate the possibility of substituting the HPIV-3 WT virus with
rHPIV3-EGFP virus in antiviral screening, viral expressed EGFP was measured and
evaluated against three cellular viability detection assays. In addition, a panel of
antiviral compounds, known to inhibit HPIV-3, was used to inhibit the rHPIV3-EGFP
virus and viral replication was assayed both by EGFP fluorescence and NR dye
uptake assays.
In the second phase of this study, an rHPIV3 virus (rHPIV3-NT) was constructed
to express a hexahistidine tag on the C-terminal end of the P protein to trace all proteins
expressed from the P gene start codon. In addition, two other rHPIV3 viruses were
constructed using the rHPIV3-NT cDNA backbone; one that eliminated the editing site in
the P gene (rHPIV3-ΔES) and a second that was deficient in the expression of the D
domain by a nonsense mutation (rHPIV3-ΔD). The hypothesis for this second study was
that the V protein is expressed from the P gene and that the D domain counteracts the
host cell’s antiviral response and inhibits the expression of interferon (IFN)-β. The
following aims were used to test this hypothesis:
1. To detect proteins expressed from the P gene start codon, the hexahistidine tagged
proteins in rHPIV3-NT virus lysates were detected with an anti-hexahistidine
antibody conjugated to horseradish peroxidase (HRP).
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2. To detect any differences in the replication rates of the three viruses, rHPIV3-NT,
rHPIV3-ΔES, and rHPIV3-ΔD, viral titers and replication curves are obtained for
each virus replicated in both MA-104 and A549 cells.
3. To detect any differences in viral mRNA transcription and viral genomic replication
rates between rHPIV3-NT, rHPIV3-ΔES, and rHPIV3-ΔD in MA-104 cells, each
process was measured by QRT-PCR.
4. To detect any differences in cytokine expression from A549 cells infected with
rHPIV3-NT, rHPIV3-ΔES, or rHPIV3-ΔD, the extracellular levels of cytokines
secreted from infected A549 cells were measured by enzyme-linked immunosorbent
assay (ELISA).
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CHAPTER 2
LITERATURE REVIEW

1. Forward vs. reverse genetics
Forward genetics, or classical genetics, is a discipline that involves the study of an
organism’s phenotype by naturally manipulating the organism’s genotype. Gregor
Mendel, “The Father of Genetics,” was the first scientist to recognize that phenotypic
traits of pea plants followed Laws of Inheritance, which are passed on through genes
(Mendel, 1866). Even though these laws do not govern the world of viruses, the
principles he laid out can be applied to viruses. Generally, each virus has a specific niche
where it grows most efficiently, but when the virus is transferred to a hostile environment
a small population of viruses may be able to replicate and survive in the new
environment. For example, drug-resistant mutant viruses arise when the WT virus is
replicated in cell culture in the presence of antiviral compounds. After several passages
of increasing drug concentration, the new drug-resistant mutant virus may replicate
normally in the presence of the antiviral compound at high concentrations; whereas the
WT virus can not. Another example is when a WT virus is replicated through several
passages in cell culture at a lower temperature than normal. In this case, the new
cold-adapted, temperature-sensitive mutant virus may not replicate at the original or
normal temperature, whereas the WT virus can replicate at both temperatures. In both
cases, the new phenotype of the mutant viruses can be traced back to natural mutations
located in the viral genome.
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On the other hand, the discipline of reverse genetics involves the deliberate
manipulation an organism’s genome to study its phenotype. The “Central Dogma” of
gene expression starts with an organism’s genetic material, which is transcribed into
mRNA and then translated into protein. The multitudes of proteins expressed by an
organism are what ultimately interact with each other in complex mechanisms and lead to
the organisms’s phenotype. The use of reverse genetics to study viral phenotypes can be
particularly useful because of the ease of manipulation, due to their relatively small
genomes, and their short and quick replication rates leading to rapid phenotypic
expression. The largest obstacle to overcome when using reverse genetics to study
viruses is the successful rescue of an infectious, recombinant virus.

2. Rescuing infectious, recombinant
viruses

2.1. DNA viruses
Viruses containing DNA genomes were the first to be genetically altered using
full-length DNA clones and homologous recombination technologies. The first virus,
whose manipulated DNA genome produced infectious, recombinant progeny, was simian
virus 40 (SV40) (Goff and Berg, 1976). SV40 was an excellent model to start the
recombinant virus revolution because of its small genome size of 5243 nt, therefore it
was relatively easy to sequence and manipulate. Also, the DNA genome of SV40 is
infectious alone because it encodes eukaryotic promoters and is transcribed and
replicated in the nucleus using the host cell’s replication and transcription machinery
(Barbanti-Brodano et al., 1970; Buchman et al., 1981). The genome of SV40 resembles
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eukaryotic DNA so much that it has served as an excellent model to study and understand
eukaryotic gene regulation, mRNA transcription, and DNA replication.
In contrast, the genome sizes of most DNA viruses are too large to clone and
manipulate directly, so the use of homologous recombination has been used to
manipulate larger DNA viruses. To genetically modify the genomes of herpes, pox, and
adenoviruses, intact viral DNA is co-transfected with recombinant DNA, which is
surrounded by viral sequences (Jones and Shenk, 1978; Mackett et al., 1982; Post and
Roizman, 1981). The result is homologous recombination between the two DNA strands
and recovery of a mixture of wild-type and recombinant viruses, which can be separated
using screening methods.

2.2. RNA Viruses

2.2.1

Positive-sense single-stranded RNA
viruses
Positive-sense single-stranded (ss)RNA viruses have the distinct advantage of

being in the same sense as mRNA, positive-sense by definition, therefore the viral
genomes are recognized by the host cell’s transcriptional machinery, which is used for
virus replication during a natural infection. The genomic RNA of positive-sense viruses
with small-to-medium sized genomes is infectious alone and results in the formation of
infectious virus progeny. To genetically manipulate these viruses, the RNA genome must
be converted into a cDNA clone first, which encodes the viral genome, and then it can be
modified using molecular biology techniques. Recombinant viral genomic RNA can then
be copied from the modified cDNA clone and transfected into cells where infectious,

recombinant virus progeny are recovered. For example, the bacteriophage Qβ was the
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first ssRNA virus to be rescued from a recombinant source, followed by Sindbis and
Semliki forest viruses (Liljestrom et al., 1991; Rice et al., 1987; Taniguchi et al., 1978).
Notably, poliovirus can be rescued from transfected cDNA clones alone, without the need
to transcribe and transfect the viral RNA genomic intermediate (Racaniello and
Baltimore, 1981).
Positive-sense, ssRNA viruses with larger genomes will encapsidate their RNA
genomes with viral protein for protection. For example a recombinant severe acute
respiratory syndrome (SARS) virus can only be successfully rescued in the presence of
the viral nucleocapsid protein (Yount et al., 2003). In addition, positive-sense,
single-stranded retroviruses are unique in that their virus genome is replicated through a
double-stranded DNA intermediate and integrates into the host cell’s genome. Therefore,
transfection of the full-length viral cDNA genome alone leads to the rescue of infectious,
recombinant virus progeny (Wei et al., 1981). Taking advantage of the fact that retroviral
genomes integrate in the host cell’s genome, recombinant retroviruses have been widely
used for eukaryotic gene expression and gene therapy.

2.2.2

Non-segmented, negative-sense
ssRNA viruses
Compared to positive-sense ssRNA viruses, the ability to rescue infectious,

recombinant, non-segmented, negative-sense ssRNA viruses are more complex. Not only
do these viruses replicate in the cytoplasm of the infected cells, but the negative-sense
RNA genome is not recognized by the host cell’s transcriptional machinery because of its
negative polarity (Friedman et al., 1981). Therefore, the viral proteins necessary for viral
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RNA synthesis are packaged into the virion in active transcriptase-replicase complexes
for immediate replication upon infection (Storey et al., 1984). This means that during the
rescue of a recombinant negative-sense virus all necessary components for viral
replication need to be present, which include the viral RNA genome, NP proteins, P
proteins, and L proteins. The NP proteins encapsidate the single-stranded viral RNA
genome, not only for protection but they also interact with themselves to facilitate
assembly of the helical nucleocapsids (Buchholz et al., 1993). In addition, the NP protein
interacts with the P protein during all aspects of viral RNA synthesis and the M protein
during virion packaging (Coronel et al., 2001; Curran et al., 1993). The P protein acts as
a cofactor that facilitates the interaction of the viral L protein with the encapsidated viral
RNA during viral RNA synthesis (Horikami et al., 1992). While the C-terminal end of
the P protein is necessary for viral RNA synthesis, a domain on the N-terminal end of the
P protein chaperones newly synthesized NP proteins to encapsidate the naked viral
genomic RNA (Fig. 2-1) (Curran et al., 1995). The L protein is the last and largest viral
protein expressed from the genome and is solely responsible for RNA polymerase
catalytic activity (Poch et al., 1990).
During the infancy of rescuing negative-sense ssRNA viruses, a basic replication
system involving minigenomes was set up to optimize the conditions of rescuing
infectious virus from cDNA. Minigenomes contain the viral 3’ and 5’ untranslated
regions (UTRs) of a particular virus flanking a single reporter gene, such as
chloramphenicol acetyl transferase (CAT) or luciferase, to measure viral RNA synthesis.
Initial experiments used this system to confirm that the presence of the NP, P, and L
proteins are required for CAT or luciferase expression and activity, although each study
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Fig. 2-1. Schematic of the HPIV-3 phosphoprotein. Three domains in the
phosphoprotein (P) include the interaction with unincorporated nucleocapsid (NP*) for
viral genomic RNA encapsidation and interaction with the large protein (L) and
encapsidated viral RNA genome (NP:RNA) for viral RNA synthesis. An editing site
(ES) exists in the middle of the P gene where the viral polymerase adds additional
non-templated G residues. This leads to the expression of three fusion proteins, P, PD,
W, and perhaps the hypothetical V*. The C protein is translated by ribosomal choice.

reported using differing ratios of the three NP, P, and L support plasmids (Durbin et al.,
1997b; Kato et al., 1996). Minigenomes also aided in the application of the “Rule of Six”
in the recovery of infectious, recombinant ssRNA viruses. The “Rule of Six” suggests
that viral replication is most efficient when the length of the viral genomes is a factor of
six ribonucleotides, most likely due to a single nucleocapsid protein binding to six
genomic ribonucleotides (Calain and Roux, 1993). Minigenomes that were a factor of six
ribonucleotides exhibited greater CAT activity compared to minigenomes in any of the
other five possibilities (Durbin et al., 1997b).
Furthermore, the transfection of the viral genome in cDNA form will not induce
the rescue of a virus. The cDNA clone needs to be transcribed into viral genomic RNA
so viral NP, P, L proteins can interact with it and induce the rescue of the recombinant
virus. Therefore, the eukaryotic cells that will host the rescue operation are infected with
a vaccinia virus that has been engineered to express a T7 RNA polymerase, vTF7-3 (Fig.
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2-2) (Fuerst et al., 1986). To control and inhibit the replication of vTF7-3, which may
interfere with the rescue of the RNA virus, and select for the recombinant RNA virus, the
cytosine β-D-arabinofuranoside (Ara-C) and/or rifampicin antiviral compounds are added
to the infected cells (Kato et al., 1996). In addition, the host cells are co-transfected with
the viral genomic cDNA plasmid and support plasmids that contain the genes for the viral
NP, P, and L proteins, whose transcription is driven by a T7 promoter. The mRNA
transcribed from the three support plasmids is further translated into the NP, P, and L
proteins. On the other hand, the T7 RNA polymerase will transcribe the viral genomic
cDNA plasmid into an RNA strand that is longer than the actual viral RNA genome
should be. To transcribe the viral RNA genome to the proper length and a factor of six
ribonucleotides, the T7 promoter is strategically placed immediately upstream of the first
nucleotide of the viral genome, separated by two G nucleotides (Durbin et al., 1997a).
On the other end of the genome, an antigenomic hepatitis delta virus ribozyme is
positioned immediately following the last nucleotide of the viral genome (Perrotta and
Been, 1991). The ribozyme will self-cleave itself from the viral RNA genome leaving
the full-length virus RNA genome intact. Another important aspect of the viral RNA
genome during the rescue of an negative-sense RNA virus is the polarity of the viral
cDNA clone. Infectious, recombinant ssRNA viruses that were rescued from
positive-sense, antigenomic cDNA clones resulted in higher titers than ssRNA viruses
rescued from negative-sense, genomic cDNA clones, even though the viral RNA genome
was itself negative-sense (Durbin et al., 1997a; Kato et al., 1996). With all of the factors
in place, which includes the expression of the viral NP, P, and L proteins and the
transcription of the positive-sense viral RNA antigenome that has been excised to the
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Fig. 2-2. Methodology for rescuing a non-segmented, negative-sense RNA virus.
1. Infection with the vaccinia virus vTF7-3, which expresses a T7 RNA polymerase.
2. Transfection and transcription of four plasmids encoding an rHPIV3 cDNA clone,
nucleocapsid protein (NP), large protein (L), and phosphoprotein (P) driven by a T7
promoter. NP, L, and P subsequently translated into proteins. 3. Encapsidation of the
genomic RNA by NP. 4. Assembly of an active transcriptase-replicase complex through
the interaction of the L, P, and encapsidated RNA. 5. Natural infection induced and
replication of the virus takes place. 6. Infectious virions bud out of the plasma membrane
of a eukaryotic cell.
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proper length, virus replication should be induced and infectious, recombinant virus
progeny should be released from the infected cells (Fig. 2-2).
Several infectious recombinant viruses have been successfully rescued from
cDNA clones, starting with the first negative-sense ssRNA virus, rabies, followed by
vesicular stomatitis virus (VSV), measles virus (MeV), Sendai virus (SeV), and HPIV-3
(Durbin et al., 1997a; Garcin et al., 1995; Lawson et al., 1995; Radecke et al., 1995;
Schnell et al., 1994). In addition, the human respiratory syncytial virus (RSV) expresses
the M2 protein that is also necessary for viral RNA synthesis and is needed for the
successful rescue of an infectious, recombinant RSV virus (Collins et al., 1995).

2.2.3

Segmented, negative-sense ssRNA
viruses
The techniques used to successfully rescue segmented, negative-sense ssRNA

viruses are even more complex because of the multiple genomic segments. The first
successful rescue of a recombinant segmented virus used minigenomes to manipulate
individual segments and rescued recombinant viruses with only one altered segment,
leaving the other segments in natural form. First, the cDNA clone for one segment was
cloned, manipulated, and transcribed into RNA in vitro. Next, the RNA segment was
reconstituted with nucleoprotein and polymerase protein to form a ribonucleoprotein in
vitro. Finally, the ribonucleoprotein was transfected into cells infected with a helper
virus that provided all other proteins and segments necessary for virus replication to
rescue infectious virions (Enami et al., 1990). A drawback to this technique is the
presence of two viruses, the helper virus and the recombinant virus, but with creative
engineering the recombinant virus can be selected for (Enami and Palese, 1991). In
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addition, the first segmented virus to be completely rescued from cDNA clones was the
Bunyamwera virus that contains three genomic segments (Bridgen and Elliott, 1996).
This virus was rescued in a similar way to non-segmented ssRNA viruses, with viral
genomic RNA and viral replication proteins transcribed by T7 RNA polymerase and
self-cleaved to the proper length by the hepatitis delta ribozyme.
On the other hand, rescuing an 8-segment influenza virus proved to be difficult
using these techniques. But, recombinant influenza viruses were rescued from cDNA
clones encoding all viral genomic segments using the host cell’s RNA transcription
system, since influenza viruses replicate in the nucleus of infected cells (Spooner and
Barry, 1977). The eukaryotic RNA Pol I promoter was used to drive the transcription
and replication of the cDNA clones encoding the viral genomic segments and terminated
by either eukaryotic termination sequences or hepatitis delta virus ribozyme cleavage
(Fodor et al., 1999; Neumann et al., 1999). In addition, the eukaryotic RNA Pol II
promoter was used to drive the transcription and expression of the viral proteins
necessary for viral replication from support plasmids. In this system, eight plasmids
encoding the eight genomic segments were co-transfected with four plasmids encoding
the viral proteins necessary for viral replication and recombinant influenza viruses were
successfully rescued. Not only did this system eliminate the need for a helper virus for
successful rescue and subsequent selection, but it also eliminated the need for the
cytotoxic infection of the recombinant vaccinia virus to supply the T7 RNA polymerase.
This system was further optimized by cloning the RNA Pol I driven genomic segments
between RNA Pol II promoter and polyadenylation sequences, therefore viral segmented
genomic RNA and viral mRNA transcription occurred simultaneously from the same
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plasmid, similar to a natural infection (Hoffmann et al., 2000). This approach reduced
the number of transfected plasmids from twelve to eight and still resulted in successful
rescue. Even with all the technological advancements in reverse genetics, only three
segmented, negative-sense ssRNA viruses have been rescued, the two mentioned above
and the 6-segment Thogoto virus (Wagner et al., 2001).

2.2.4

Segmented, double-stranded RNA
viruses
The genomes of double-stranded (ds)RNA viruses are segmented, similar to

influenza viruses, but dsRNA viruses replicate in the cytoplasm, which further increases
the complexity of successful rescue from cDNA clones. Initial studies to rescue
infectious, recombinant dsRNA viruses resembled the early system to rescue segmented
negative-sense RNA viruses where individual recombinant viral RNA genomic segments
were transcribed in vitro. Recombinant viruses were rescued with the transfection of the
individual RNA segment and the aid of a helper virus, which was separated from the
recombinant virus using screening techniques (Roner et al., 1997). Recently, a
recombinant Bluetongue dsRNA virus has been rescued by co-transfecting all viral RNA
segments, which were transcribed in vitro (Boyce et al., 2008). In addition, the T7
promoter/hepatitis delta ribozyme system has been used to successfully rescue a
segmented dsRNA reovirus completely from cDNA, without the need to co-transfect
support plasmids encoding the viral proteins necessary for virus replication (Kobayashi et
al., 2007).
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3. Reverse genetics applications

3.1. Viral induced expression of a foreign
gene
One application using reverse genetics is to express a protein, which is foreign to
the viral host, from a distinct gene on the virus genome. For the foreign gene to be
recognized and expressed from the viral genome it must mimic a viral gene by encoding
the necessary viral mRNA regulation sequences. The genomes of the Paramyxovirinae
subfamily, which are non-segmented, negative-sense, ssRNA viruses, contain a series of
6–7 distinct gene units, which may contain one or more open reading frames (ORF). The
main proteins expressed from the distinct gene units are NP, P, M, F, HN or hemagglutin
(H), and L; also SH for rubulaviruses (Fig. 2-3A). The series of gene units are flanked by
3’ leader and 5’ trailer UTRs that are essential for viral transcription and replication
regulation (Calain and Roux, 1995). Each gene unit is separated by semi-conserved
intergenic regions that consist of gene end, intercistronic, and gene start sequences (Fig.
2-3B). Therefore, when inserting a foreign gene as a distinct gene unit, the new gene unit
must contain the gene end, intercistronic, and gene start sequences to be effectively
expressed through viral mRNA transcription.
During viral mRNA synthesis, the viral RNA polymerase recognizes the gene end
sequence and stutters, adding non-templated adenosine (A) residues to create a poly-A
tail. The viral RNA polymerase then reengages viral mRNA transcription at the gene
start sequence for the next gene unit. The viral RNA polymerase will sometimes fail to
reengage mRNA transcription for the downstream gene, which results in fewer mRNA
transcripts for downstream genes compared to upstream genes transcribed from the same
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Fig. 2-3. Organization of the major genes units encoded in the Paramyxovirinae
genomes. (A) The viral genomes consists of the following major features in order: 3’
leader (le), nucleocapsid protein (NP), phosphoprotein (P), matrix protein (M), fusion
protein (F), hemagglutinin-neuraminidase (HN) or hemagglutinin (H), large protein (L),
and 5’ trailer (tr). (B) Semi-conserved gene end, intercistronic, and gene start sequences
of HPIV-3 at the gene junctions NP-P (1), P-M (2), M-F (3), F-HN (4), and HN-L (5).

template. This phenomenon is called transcriptional polarity and ultimately leads to less
protein expressed from the downstream gene units in a gradient fashion (Wertz et al.,
1998). This phenomenon can be used advantageously for regulation purposes by cloning
the new foreign gene unit into various locations on the viral genome. For example, if the
expression of the foreign gene is to be upregulated then the gene unit could be cloned
towards the 3’ end of the viral genome, but if the foreign gene is to be downregulated
then the gene unit could be cloned towards the 5’ end of the viral genome. Furthermore,
if the foreign gene unit is to be cloned as the first gene on the viral genome then a second
viral regulatory sequence needs to be taken into consideration. Past the 3’ leader UTR
are three G ribonucleotides equally separated by five ribonucleotides, which correspond
to one complete turn of the 3-dimensional helical encapsidated RNA genome. This
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location is thought to co-regulate viral replication perhaps through the assembly and
binding of the L-P complex with the encapsidated RNA genome (Tapparel et al., 1998).
This method has been used to effectively express a foreign gene from the genome
of infectious, recombinant ssRNA viruses for many purposes. For example, a
recombinant SeV, which is non-pathogenic to humans thus a prime candidate for vaccine
development and gene transfer, has been used as a expression vector in gene transfer to
deliver foreign eukaryotic genes to neurons and airway epithelium (Shirakura et al., 2003;
Yonemitsu et al., 2000). In addition, several recombinant paramyxoviruses have been
developed that express other viral surface proteins to be used as vaccines. The ebolavirus
glycoprotein and the RSV fusion protein have been expressed from recombinant HPIV-3
and SeV viruses, respectively, and have resulted in protective immunity against
ebolavirus and RSV, respectively (Bukreyev et al., 2006; Zhan et al., 2007). A third area
where the insertion of a foreign gene into a recombinant virus has been used is for the
expression of a reporter gene for the purpose of tracing the viral infection. A
recombinant HPIV-3, strain JS, has been engineered to express the EGFP protein and was
used to trace the infection of HPIV-3 exclusively to the apical surface of ciliated airway
epithelium by attaching to α2-6-linked sialic acid receptors (Zhang et al., 2005).
3.1.1

Antiviral assays detecting virus
expressed reporter genes
Another benefit of a recombinant virus that expresses a reporter gene is the ability

to detect and measure virus replication in real-time, which is directly linked to the
expression of the foreign reporter gene. This measurement of real-time replication has
direct implications in antiviral compound screening in vitro. When using the traditional
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NR dye uptake assay to measure antiviral compound effectiveness, complete cell
destruction is necessary to obtain effective and reliable assay results. A major drawback
to this type of assay for some viruses is the inability to produce detectable amounts of
CPE or long incubation times that are needed for some viruses to completely lyse the cell
monolayer. Viral incubation times may extend up to 14 days for some viruses and is
problematic because the cell control monolayer may not survive that long. Other viruses,
such as SARS and influenza, do not suffer from this problem because of their short
incubation periods and lytic nature of their replication cycle (Barnard et al., 2004; Smee
et al., 2001). On the other hand, HPIV-3 and RSV form syncytia during the onset of
infection and the syncytia lyse later (Lin et al., 1999). The early syncytia formation is
problematic because, even though viral CPE can be seen within days, syncytia cells
absorb similar amounts of NR compared to intact cells (Smee et al., 2002). Therefore, it
is necessary for the syncytia to completely lyse before the detection assay is conducted.
A detection system, such as a recombinant virus expressing a reporter gene that
can be measured in real-time may shorten the amount of time needed to complete the
antiviral assay and allow direct CPE measurement. This has been accomplished for
antiviral compound screening purposes by inserting the gene for the green fluorescent
protein into the genomes of recombinant ebolavirus and cytomegalovirus (Marschall et
al., 2000; Towner et al., 2005). In addition, the luciferase gene has been inserted into the
genome of a recombinant West Nile virus (Puig-Basagoiti et al., 2005). HPIV-3 exhibits
a 6–8 day incubation period and, therefore, is a candidate for such a purpose (Lin et al.,
1999). A recombinant HPIV-3 virus has been constructed that expresses a green
fluorescent protein and was used to screen an antiviral compound library (Mao et al.,
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2008). But it was not reported to have been extensively studied and validated as a
suitable replacement for the wild-type virus in cell-based antiviral assays.

3.1.2

Traditional antiviral detection
assays
Traditionally, to measure the efficacy of antiviral compounds, several cell

viability detection systems involving colorimetric, luminescence, or fluorescence have
been used. The colorimetric gold standard uses neutral red, which is absorbed by
lysosomes of intact cells and can be measured empirically by a spectrophotometer
(Anderson and Orci, 1988; Finter, 1969; Lowik et al., 1993; McLaren et al., 1983;
Paragas et al., 2004; Smee et al., 2002). One major problem with neutral red is the
formation of thread-like crystals that form on the cell monolayer, most likely caused by
poor solution preparation and may be accelerated by certain compounds. The neutral red
crystals can not be eliminated with numerous rinses and are readily dissolved in the
extraction process, thereby increasing the absorbance values and skewing the results. In
addition, because of the colorimetric nature of the assay, certain test compounds may
have absorption spectra similar to neutral red, which may also skew the results. Even
though neutral red can be added directly to the test medium, it also requires lengthy
absorption times, subsequent washes, and extraction with ethanol, making this method
time consuming and labor intensive. The washes are also problematic because,
depending on the cell type used in the assay, the cell monolayer could be washed away.
A second detection method uses the substrate 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT) (Pauwels et al., 1988; Watanabe et al., 1994).
MTT is a yellow tetrazolium salt that is reduced by a mitochondrial reductase in cells to
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form water-insoluble purple formazan crystals, which can be measured empirically
(Mosmann, 1983). MTT is similar to neutral red in that it is absorbed by intact cells, but
differs by being chemically modified once inside a cell. One problem with the MTT
assay is that the presence of phenol red in the test medium can interfere with the
spectrophotometer measuring the absorbance, and it is recommended that the cell
monolayer be incubated in phenol-free medium or at least be replaced with phenol-free
medium during absorption. One major disadvantage of the MTT assay is that the purple
formazan crystals are formed through an enzymatic reaction inside the cell. Not only
could the antiviral compound being tested inhibit virus replication, it may also inhibit
purple crystal formation, thus skewing the absorbance values.
A third colorimetric assay measures the activity of lactate dehydrogenase (LDH)
that has leaked out of dead or dying cells (Baba et al., 2005; Mori et al., 1995; Watanabe
et al., 1995). A substrate, 2-p-(iodophenyl)-3-(p-nitrophenyl)-5-phenyltetrazolium
chloride (INT), is reduced by LDH, in a NADH-coupled reaction, to form a water-soluble
red formazan, which can be measured empirically (Hinman and Blass, 1981). A
difference between the LDH assay and the two methods mentioned above is that the
supernatant, which contains LDH that has leaked from dead or dying cells, is removed
from the cell monolayer during the LDH assay. This assay increases the handling of the
samples but the incubation times and solubility issues are reduced.
Another type of assay is the CellTiter-Glo® Luminescent Cell Viability Assay
(Promega, Madison, WI), which measures the adenosine triphosphate (ATP) generated
by intact cells (Noah et al., 2007). When luciferase and luciferin are added to the test
medium that contains ATP, light is emitted and the amount of light generated is
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proportional to the health of the cell monolayer. The benefits to this assay are the direct
addition of reagents to the test medium, short incubation, and high sensitivity.
Even though the luminescence assay solves the handling and time disadvantages
of the colorimetric assays, a major issue arises that is present in the colorimetric assays as
well. A major problem with most cell viability assays is that they are designed to detect
any cell death and do not differentiate between drug toxicity and viral CPE. By
conducting a parallel drug toxicity assay, the two factors can be mathematically
separated, although it is assumed that the differences measured in the assay are due to
drug toxicity and CPE independently. This assumption ignores the possibility of positive
or negative compounding effects from potential interactions between the drug and virus.
Therefore, a detection system that can directly measure a change in virus replication
independently of drug toxicity would be preferable. Foreign reporter proteins that are
expressed from the genomes of recombinant viruses and detected in real-time can
measure virus replication directly regardless of drug toxicity and could be a possible
solution to the problem.

3.2. Characterization of viral accessory
proteins using recombinant knockout
viruses
A second application using reverse genetics is to study the functions of viral
genes through mutational analysis. The cDNA clone for a ssRNA virus can serve as
backbone for genetic manipulation and infectious, recombinant viruses can be rescued
from it, assuming the mutation is not deleterious to the virus. The recombinant parent
and mutant viruses can then be measured using traditional and modern virological

23
techniques and compared to each other. If any differences in growth characteristics, for
example, are seen between the two recombinant viruses, the change may be attributed to
the mutations of the mutant virus. For the most part, this method has been used to study
the accessory proteins expressed by ssRNA viruses because they are generally not
essential for virus replication, even though they may play part in replication in some way.
Most other genes in the viral genome are essential for viral replication and any deliberate
knockouts or mutations may render the recombinant virus uninfectious. Generally, the
accessory proteins are involved in counteracting the host cell’s antiviral response,
discussed later.
The accessory proteins are expressed from mRNA transcribed from the P gene of
most paramyxoviruses genomes. The P gene on the HPIV-3 genome contains additional
ORFs that encode for the C, W, and PD proteins, in addition to the P protein (Fig. 2-2)
(Galinski et al., 1986; Galinski et al., 1992). Other paramyxoviruses encode for more
accessory proteins, such as, the V protein expressed by all paramyxoviruses except
HPIV-3 and HPIV-1, two Y and a second C’ protein expressed by SeV and HPIV-1, and
the I protein expressed by rubulaviruses (Giorgi et al., 1983; Matsuoka et al., 1991). The
translation of the C and Y proteins in initiated by ribosomal choice or shunting and the V,
W, I, PD proteins are transcribed by mRNA editing (Latorre et al., 1998).

3.2.1

C proteins
The C protein is about 170 amino acids long, overall basic in charge, and a small

percentage of sequence homology is shared by all members of the Paramyxovirinae. All
members of this subfamily express the C protein in some way. The individual C proteins
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expressed by respiroviruses, morbilliviruses, and henipaviruses are translated by
ribosomal choice (Bellini et al., 1985; Galinski et al., 1986; Giorgi et al., 1983). The start
codon for the C protein is approximately 10 ribonucleotides downstream of the start
codon for the P protein (Fig. 2-2). During the initiation of protein translation, the
ribosome may read through the start codon for the P protein and initiate translation at the
start codon for the C protein. Also, the SeV and HPIV-1 viruses encode for a second C’
protein whose start codon is upstream of the P protein start codon and is also translated
by ribosomal choice (Giorgi et al., 1983). In addition, the SeV and HPIV-1 viruses
encode for two Y proteins, also located on the 5’ end of the P gene mRNA, but
translation is initiated by ribosomal shunting (Latorre et al., 1998). Ribosomal shunting
occurs when the ribosome “jumps” a portion of the mRNA and initiates translation at a
start codon further downstream; at least 80 ribonucleotides downstream of the P protein
start codon for the SeV virus. For the members of the rubulaviruses and avulaviruses,
ribosomal choice or shunting does not occur, but the P protein is translated as a fusion
protein with the C-terminal cofactor end of the P protein fused to a C-like protein
N-terminal end (McGinnes et al., 1988; Thomas et al., 1988).
The C proteins seem to be involved in some aspect of regulating viral RNA
synthesis. The titers of recombinant HPIV-3 and SeV viruses, which are deficient in the
expression of their C proteins, are restricted in cell culture (Durbin et al., 1999; Kurotani
et al., 1998). However, the specific aspect of viral RNA synthesis is different for each
virus. The SeV virus C protein regulates genomic replication, whereas the HPIV-3 virus
C protein regulates viral mRNA transcription (Cadd et al., 1996; Malur et al., 2004).
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3.2.2

Proteins expressed by mRNA editing
The P gene of all members in the Paramyxovirinae subfamily contains an mRNA

editing site where the viral polymerase stops and stutters, adding non-templated G
residues during viral mRNA transcription. This results in frame shifts in the open
reading frame of the mRNA and leads to the translation of three fusion proteins with
identical N-terminal ends and different C-terminal ends. For HPIV-3, the proteins
expressed in this way are the P, W, and PD (Fig. 2-2) (Galinski et al., 1992). The V and I
proteins are also expressed in this manner by other members of the Paramyxovirinae
subfamily (Cattaneo et al., 1989; Thomas et al., 1988; Vidal et al., 1990). The stop
codons for the W protein, expressed in respiroviruses, morbilliviruses, and henipaviruses,
and the I protein, expressed in rubulaviruses and avulaviruses, appear shortly after the
editing site and lead to the removal of the C-terminal cofactor end of the P protein. The
main functions of the W and I proteins have been theorized to be that of the remaining
N-terminal ends. In respiroviruses, morbilliviruses, and henipaviruses, the function of
the W protein has been attributed to chaperoning unincorporated NP proteins to
encapsidate naked genomic RNA. In rubulaviruses and avulaviruses, the function of the I
protein has been attributed to the functions of the C protein.
Another fusion protein is the V protein, which is characterized by a highly
conserved, C-terminal, cysteine-rich domain that binds two zinc atoms to form a
zinc-finger structure (Paterson et al., 1995). It is expressed by most members of the
Paramyxovirinae, except for HPIV-3 and HPIV-1 (Cattaneo et al., 1989; Thomas et al.,
1988; Vidal et al., 1990). Even though the cysteine-rich domain is not encoded anywhere
within the HPIV-1 genome, it is located in the HPIV-3 antigenome in the same reading
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frame as the W protein downstream of 2 or 3 stop codons, depending upon the virus
strain (Fig. 2-1 and 2-4) (Galinski et al., 1992; Matsuoka et al., 1991). Although the
HPIV-3 antigenome may contain the ribonucleotide sequence that encodes the
cysteine-rich domain characteristic of the V protein, it is still not known if it is expressed
at all. In the only study reporting research pertaining to the HPIV-3 V protein, the D and
V domains were silenced individually and simultaneously (Durbin et al., 1999). No
attenuation in viral titers was seen when the individual or simultaneous knockout viruses
were used in vitro or individually in vivo, but attenuation was seen when the cistrons
were silenced simultaneously in vivo. These data suggest that the D and V domains were
expressed and that together they played a role in the host cell’s antiviral response. The
main function of the V protein expressed by other paramyxoviruses has been attributed to
counteracting the antiviral response, discussed later. To date no virus-specific function of
the V protein has been found.
More recently, the PD protein of HPIV-3, which is the fusion of the N-terminal
end of the P protein and the C-terminal D domain, was detected in vitro. Three nuclear
localization signals were identified within the PD protein that directed the intracellular

SeV
BPIV-3
HPIV-3

KGHRREHIIYERDGYIVNESWCNPVCSRIRVISRRELCVCKACPKICKLCRDDI
RGHRREHSIYRKGDYIITESWCNPICSKIRPIPRQESCVCGECPKQCRYCIKDR
EGYRREQSIYREGNYSIAESWCNPIYIKIRFISRQTSCMCSKCTKQCRYCIKDR

Fig. 2-4. Protein alignment of the respiroviruses V domain. The amino acid sequence of
the V domain aligned from Sendai virus (SeV), Bovine and Human parainfluenza type 3
viruses (B or HPIV-3). The conserved amino acids shared by all members of the
Paramyxoviridae family, except HPIV-3 and HPIV-1 (star).
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localization of the PD protein to the nucleus, but its function remains a mystery (Wells
and Malur, 2008).

3.2.3

Host cell’s antiviral response
When a ssRNA virus infects a cell, the virus produces intermediate structures in

the host cell’s cytoplasm that are unique to the replicating virus and the host cell can
recognize them as foreign. In response, protein receptors inside the infected host cell,
which bind to the viral intermediate RNA structures, initiate the primary interferon
pathway that ultimately expresses interferons, which are secreted from the infected cell.
Two of the viral structures that the host cell can recognize as foreign are ds RNA and
5’-triphosphate or uncapped ssRNA. The cellular proteins that bind these structures
through a RNA helicase domain are the melanoma differentiation associated gene
(MDA)-5 and the retinoic acid inducible gene (RIG)-1, both of which initiate the primary
interferon pathway. While MDA-5 binds viral dsRNA intermediates, RIG-1 binds the
5’-triphosphate ends of ssRNA, which are characteristic of viral transcribed mRNA and
genomic RNA, and also short dsRNA intermediates, which are characteristic of viral
RNA secondary structures (Fig. 2-5) (Hornung et al., 2006; Kang et al., 2002; Kato et al.,
2008; Pichlmair et al., 2006). When these proteins bind viral RNA, their N-terminal
caspase recruitment domain (CARD) interacts with mitochondrial antiviral signaling
(MAVS) or IFN-β promoter stimulator (IPS)-1 proteins (Kawai et al., 2005; Seth et al.,
2005). In turn, MAVS/IPS-1 activates TRAF family member-associated NF-κB activator
(TANK) binding kinase (TBK)-1 and IkappaB kinase (IKK)ε, which in turn, leads to the
homo- or hetero-dimerization of the interferon regulatory factors (IRF)-3 and -7 and their
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translocation into the nucleus (Kumar et al., 2006; Sun et al., 2006). Once in the nucleus,
IRF-3/7 dimers promote the expression of IFN-β and the regulated on activation normal
T cell expressed and secreted (RANTES) proteins, both of which are secreted from the
infected cell (Au et al., 1995; Lin et al., 2000).
Extracellular IFN-β then activates the secondary interferon pathway in an
autocrine and paracrine fashion by binding to type 1 IFN receptors (IFNAR), which in
turn activates the Janus kinase-signal transducers and activators of transcription
(JAK-STAT) signaling pathway (Fig. 2-5) (Levy and Darnell, 2002). Ultimately,
STAT-1 and -2 proteins are phosphorylated, dimerized, and translocated to the nucleus
where they associate with IRF-9 to form IFN-stimulated gene factor (ISGF)-3 complexes.
Finally, this complex binds to IFN-stimulated response elements (ISREs) to promote the
expression of IFN-stimulated genes (ISGs). For example, the 2'-5' oligoadenylate
synthetase enzyme is an ISG that is expressed in response to viral invasion and activates
RNaseL, which degrades all RNA, viral and cellular, inside the infected cell (Zhou et al.,
1993).

3.2.4

Viral antiviral response antagonists
The paramyxovirus V and C proteins work in concert to inhibit both the primary

and secondary IFN response. To initiate the primary IFN antiviral response, cells
infected with paramyxoviruses primarily use the RIG-1 protein sensor (Kato et al., 2006).
To counteract this response, the SeV virus C protein inhibits some aspect of the RIG-1
signaling pathway but not the MDA-5 signaling pathway (Fig. 2-5) (Strahle et al., 2007).
As a second measure, the paramyxovirus V proteins also inhibit the antiviral response by
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Fig. 2-5. Primary and secondary interferon responses. The primary interferon response
is initiated by the presence of either uncapped RNA or dsRNA, which activates RIG-1 or
MDA-5 sensors. These sensors then activate MAVS/IPS-1, which in turn activates the
TBK-1/IKKε kinases. These kinases then phosphorylate IRF-3/7, which dimerizes and
translocates to the nucleus. Once in the nucleus the IRF-3/7 transcription factors induce
the expression of IFN-β, which is secreted out of the cell. Once outside the cell, the
secondary interferon response is activated by IFN-β binding to the IFNAR receptor,
which activates the JAK/STAT pathway. The Jak-1/TYK-2 kinase phosphorylates
STAT-1/2, which dimerizes and translocates to the nucleus and interacts with IRF-9 to
form the ISGF-3 transcription factor. This transcription factor then binds to ISRE
sequences and induces the expression of ISGs. The paramyxovirus V proteins bind and
inhibit MDA-5, thus preventing the primary IFN response. The Me V protein also
inhibits IRF-7 to prevent IFN-β expression. The SeV C protein interferes with RIG-1
signaling, thus preventing the primary IFN response. The paramyxovirus C protein also
prevents the secondary IFN response by binding and inhibiting STAT activation.
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binding to MDA-5 and, thus, competing with and preventing dsRNA binding (Fig. 2-5)
(Andrejeva et al., 2004; Childs et al., 2007; Childs et al., 2009; Komatsu et al., 2007). In
addition, the MeV V protein competes with IRF-7 for binding to and phosphorylation by
IKKα, therefore, preventing the primary IFN response that is initiated by both MDA-5
and RIG-1 (Pfaller and Conzelmann, 2008). On the other hand, the single-stranded
genomic RNA for RSV interacts with the cellular La protein that prevents the binding of
and detection by RIG-1, thus, inhibiting the primary IFN antiviral response (Bitko et al.,
2008).
Furthermore, the paramyxovirus C proteins interfere with secondary IFN
signaling of the infected host cell by binding and inducing ubiquitination of STAT1 and,
thus, proteosome-mediated degradation of STAT1 (Fig. 2-5) (Didcock et al., 1999;
Garcin et al., 2002; Palosaari et al., 2003). Also, the HPIV-3 virus C protein binds and
prevents the phosphorylation of the STAT proteins, therefore, inactivating STAT and
preventing the secondary IFN antiviral response (Malur et al., 2005). In conclusion,
paramyxoviruses have developed multifaceted and complex mechanisms, involving viral
and cellular proteins, in which to control the host cell’s antiviral response and propagate
the virus progeny.
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CHAPTER 3
A RECOMBINANT, INFECTIOUS HUMAN PARAINFLUENZA
VIRUS TYPE 3 EXPRESSING THE ENHANCED GREEN
FLUORESCENT PROTEIN FOR USE IN HIGH-THROUGHPUT
ANTIVIRAL ASSAYS 1

Abstract
The ability to rescue an infectious, recombinant, negative-stranded RNA virus
from a cDNA clone has led to new opportunities for measuring viral replication from a
viral expressed reporter gene. In this study, the EGFP gene was inserted into the HPIV-3
antigenome and a recombinant, infectious virus was rescued. Maximum EGFP
expression levels, measured by fluorescence, were seen at day 3. Comparison of a 3-day,
viral expressed EGFP fluorescence assay to a 7-day, neutral red assay, based on complete
cell destruction in virus infected MA-104 cells, yielded Z´-factor values of 0.83 and 0.70,
respectively. A 3-day, endpoint EGFP-based antiviral assay and a 7-day, endpoint
neutral red based antiviral assay were run in parallel to establish antiviral sensitivity
profiles of 23 compounds based on selective index values. Using a selective index
threshold of 10, the EGFP-based antiviral assay had a sensitivity of 100% and a
specificity of 54%. Thus, the use of an EGFP-based antiviral assay for testing potential
antiviral compounds against HPIV-3 in a high-throughput format may be justified.
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1. Introduction
The advent of therapeutic antiviral compounds for human treatment begins with
in vitro testing and the successful inhibition of a virus prior to further assessment. To
measure the efficacy of these drugs, cell-based antiviral assays involving colorimetric and
luminescence detection systems have been used. Colorimetric assays often measure
absorption of NR or MTT, which are taken up by intact cell cells as indicators of cell
health. Neutral red measures membrane integrity by being absorbed by lysosomes, while
MTT, once inside the cell, is reduced from a yellow tetrazolium salt into water-insoluble
purple formazan crystals by a mitochondrial reductase (Barnard et al., 2004; Finter, 1969;
Watanabe et al., 1994). The time consuming and labor intensive nature of these methods
have proven to be drawbacks (Smee et al., 2002). An alternative type of detection
method is the CellTiter-Glo® Luminescent Cell Viability Assay (Promega, Madison, WI),
which measures the ATP generated by intact cells (Noah et al., 2007). It is claimed that
this assay is more sensitive, less time consuming, and less labor intensive. Even though
the luminescence assay may solve the disadvantages of the colorimetric assays, several
issues arise that are also common to colorimetric assays as well.
A major problem with most cell viability assays is that they are designed to detect
any cell death and do not differentiate between drug toxicity and viral CPE. By
conducting a parallel drug toxicity assay, the two factors can be mathematically
separated, although it is assumed that the differences measured in the assay are due to
drug toxicity and CPE independently. This assumption ignores the possibility of positive
or negative compounding effects from potential interactions between the drug and virus.
A second problem is the inability for some viruses to produce detectable amounts of CPE
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and/or the long incubation times needed to reach complete cell monolayer destruction,
which is often required for accurate dye uptake assays. For the colorimetric and
luminescent antiviral assay to be effective and reliable complete destruction of the virus
infected cell controls is necessary to obtain significant signal-to-background ratios
compared to uninfected cell controls. In addition, viral incubation times may extend up
to 14 days for some viruses, which is problematic because the uninfected cell controls
may not survive that long. A third problem is virus induced syncytia formation of the
infected cells that do not completely lyse until the later stages of the virus infection.
Early syncytia formation is problematic because they absorb similar amounts of neutral
red or MTT compared to uninfected cells, even though viral CPE can be visually detected
within a few days (Smee et al., 2002). Therefore, it is necessary to wait for complete
destruction of the virus induced syncytia so dye uptake assays can differentiate between
uninfected cells and cells impacted by syncytial formation. Therefore, a detection system
that can directly measure changes in virus replication independently of drug toxicity in a
short amount of time would be preferable.
One strategy for enhancing sensitivity and decreasing the incubation times of an
assay would be to construct a recombinant virus that expresses a reporter gene. For
example, a gene for a fluorescent protein could be cloned directly into a viral genome that
would be expressed in proportion to virus replication and allow direct measurement of
virus replication independently from drug toxicity. This has been accomplished for
antiviral compound screening purposes by inserting the gene for the green fluorescent
protein into the genomes of the ebolavirus and cytomegalovirus (Marschall et al., 2000;
Towner et al., 2005). Thus, for syncytial forming viruses, such as HPIV-3, a similar
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approach would be very useful in reducing the time needed to complete an antiviral
assay.
Two rHPIV3 viruses have been constructed that express a green fluorescent
protein, but they have not been extensively studied and validated for use in cell-based
antiviral assays. One such virus, strain JS, was used to trace the infection of the
recombinant HPIV-3 virus in lung epithelium (Zhang et al., 2005). The second virus,
strain 47885, was used to screen a library of potential antiviral compounds, yet specific
details on replication differences of the recombinant virus expressing the fluorescent
protein, compared to the wild-type strain were not discussed (Mao et al., 2008). In this
paper, an rHPIV3 expressing EGFP, rHPIV3-EGFP, was rescued and evaluated for its
use in antiviral assays by comparing it side-by-side with both the HPIV-3 WT and the
recombinant HPIV-3 strains. Slight differences in virulence between the rHPIV3-EGFP
virus and the HPIV-3 WT virus in cell culture may validate the possibility of substituting
the rHPIV3-EGFP for the HPIV-3 WT virus in primary, high-throughput antiviral assays.

2. Materials and methods

2.1. Cells and viruses
Human cervical carcinoma cells (HeLa) were obtained from the American Type
Culture Collection (ATCC, Manassas, VA) and maintained at 37°C and 5% CO2 in
minimal essential medium (MEM, Hyclone Laboratories, Logan, UT) supplemented with
10% fetal bovine serum (FBS, Hyclone Laboratories), 0.1 mM non-essential amino acids
(NEAA, Invitrogen, Carlsbad, CA), and 1 mM sodium pyruvate (Invitrogen). Embryonic
African green monkey kidney cells (MA-104) were obtained from the ATCC and
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maintained at 37°C and 5% CO2 in MEM supplemented with 10% FBS. A recombinant
vaccinia virus that expresses the bacteriophage T7 RNA polymerase, vTF7-3, generously
provided by Dr. Bernard Moss, was propagated in HeLa cells (Fuerst et al., 1986).
HPIV-3 WT, isolate 14702, (J. Bouvin, Hosp. St. Justine, Montreal, Canada) was
propagated in MA-104 cells. During the antiviral assays, MA-104 cells were incubated
in MEM supplemented with 2% FBS and 50 µg/ml gentamicin (Sigma Chemical
Company, St. Louis, MO).

2.2. Antiviral compounds
2-[(2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)oxolan-2-yl]3-sulfanylidene-1,2,4-triazin-5-one (2-thio-6-azauridine) was obtained from Sigma and
the remainder of the antiviral compounds, including 1-[(2R,3R,4S,5R)-3,4-dihydroxy5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide (ribavirin),
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole3-carboximidamide (ribamidine), 2-[(2R,3R,4S,5R)-3,4-dihydroxy5-(hydroxymethyl)oxolan-2-yl]-1,3-selenazole-4-carboxamide (selenazofurin),
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-ethynylimidazole4-carboxamide (EICAR), 6-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy5-(hydroxymethyl)oxolan-2-yl]-5H-imidazo[4,5-c]pyridin-4-one (3-deazaguanosine), and
1-(4-methoxybenzyloxy) adenosine, were obtained from the repository of the NIAID
Antiviral Substances Program, NIH. Also obtained from the repository were CS-978,
CS-1164, CS-1196, CS-1227, PSI-0194, PSI-5067, PSI-5095, PSI-5098, PSI-5452,
PSI-5449, PSI-5741, PSI-5746, PSI-5747, PSI-5852, and PSI-5990 nucleoside analog
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compounds that were submitted by and used with permission from Dr. Michael Otto of
Pharmasset, Inc. The DAS181 fusion protein, also obtained from the repository, was
submitted by and used with permission from Dr. Fang Fang of NexBio, Inc. (Malakhov et
al., 2006).

2.3. Plasmid construction
Three overlapping cDNA strands, encompassing viral bases 1–5267, 5249–11366,
and 11284–15453, were generated from RNA isolated from a HPIV-3 WT, strain 14702,
infection. Forward and reverse primers were derived from the consensus sequence
between three known HPIV-3 strains, 47885, JS, GPv (Galinski, 1991; Ohsawa et al.,
1998; Stokes et al., 1992). To generate the 1–5267 cDNA segment the
5’-CCGACGTCTTAATTAATACGACTCACTATAGGACCAAACAAGAGAAGAA
ACTT-3’ forward primer, which contains AatII and PacI restrictions sites (bolded) and a
T7 promoter (underlined) and the 5’-GGTCACCACAAGAGTTAGA-3’ reverse primer
were used. To generate the 5249–11366 cDNA segment the
5’-TCTAACTCTTGTGGTGACC-3’ forward primer, which contains a natural BstEII
restriction site (bolded) and the 5’-ATTCATCCCAAGGGCAATA-3’ reverse primer
were used. To generate the 11284–15453 cDNA segment the
5’-AGAATGGTTATTCACCTGTTC-3’ forward primer and the
5’-GAGAAGCACTCTGTGTGGTAT-3’ reverse primer, which contains a mutated
DraIII restriction site (bolded) with the two mutations, A to C and T to G (underlined),
were used. The cDNA segments were inserted into the SmaI site of pUC19 (New
England Biolabs, NEB, Ipswich, MA). Clones were sequenced in both directions to
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assure accuracy. An SphI site in the 5249–11366 cDNA segment was destroyed by
mutating A to G, viral base position 8635, using the QuikChange® XL Site-Directed
Mutagenesis (Stratagene, La Jolla, CA) kit and the forward primer,
5’-CTTAGGAGCAAAGCGTGCTCAGAAAATGGACACTG-3’, and reverse primer,
5’-CAGTGTCCATTTTCTGAGCACGCTTTGCTCCTAAG-3’.
To confirm the sequence of the 3’ end of the HPIV-3 WT genome, a poly(A) tail
was added to the 3’ end of the isolated HPIV-3 WT RNA using the Poly(A) Tailing Kit
(Ambion, Austin, TX). The tailed RNA was amplified by reverse transcriptase
polymerase chain reaction (RT-PCR) using a 60-nt poly(T) oligonucleotide, as the
forward primer, and 5’-TCGTTTTAGATCCTTCTCAATCA-3’, as the reverse primer.
To sequence the 5’ end of the HPIV-3 WT genome, the SMART™ RACE cDNA
Amplification Kit (Clontech) was used. An HPIV-3 WT specific primer,
5’-GGAAGGAGCCATCGGCAAATCAGAAG-3’, was used to prime cDNA synthesis
and also used in the polymerase chain reaction (PCR) amplification step as the forward
primer. The PCR products from both the 3’ and 5’ reactions were sequenced to complete
the HPIV-3 WT 14702 genome (GenBank accession no. EU424062).
Two oligonucleotides were generated to contain a 14 base pair overlap between
each other,
5’-TTTTTGTGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGTTAAT
TAAGAGGGTGACCCTGCACAGAGTGCC-3’ and
5’-TTTTTGTAAAAAACCCCTCAAGACCCGTTTAGAGGCCCCAAGGGGTTATGC
TAGTTAGGTACCCGGGCACTCTGTGCAG-3’. The oligonucleotides were
annealed together and extended using Sequenase™ Version 2.0 DNA polymerase (USB
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Corporation, Cleveland, OH). The fragment was inserted into the SmaI site of pUC19
and named pUC19-A. The completed segment contained the PacI, BstEII, DraIII, SmaI,
and KpnI sites (bolded), a T7 termination sequence (underlined), and two vaccinia virus
termination sequences flanking each end (italicized). A second set of oligonucleotides
were annealed, extended, and inserted into pUC19 in the same manner,
5’-ACCACACAGAGTGCTTCTCTTGTTTGGTGGGTCGGCATGGCATCTCCACCTCC
TCGCGGTCCGACCT-3’ and
5’-GGCCGGTACCTCCCTTAGCCATCCGAGTGGACGACGTCCTCCTTCGGATG
CCCAGGTCGGACCGCGA-3’. The completed segment, pUC19-R, contained the KpnI
and DraIII restriction sites (bolded), the antigenomic hepatitis delta virus ribozyme
(underlined) (Perrotta and Been, 1991), and the viral bases 15435–15462 (italicized).
pUC19-R, digested with DraIII and KpnI, resulted in a 108 nt segment that was inserted
into the same sites of pUC19-A and was renamed pUC19-B. After destroying the native
SphI site in pUC19-B and renamed pUC19-C, an adapter, using the oligonucleotides
5’-GTGACCGCGCATGCCCACAGA-3’ and 5’-GTGGGCATGCGCG-3’, was
inserted into the DraIII and BstEII sites of pUC19-C to encode a SphI site (bolded) and
renamed pUC19-D. Next, the 5249–11366 cDNA segment was digested with BstEII and
SphI, inserted into the same sites of pUC19-D, and renamed pUC19-F. Then, the 1–5267
cDNA segment was digested with PacI and BstEII, inserted into the same sites of
pUC19-F, and renamed pUC19-G. Finally, the 11284–15453 cDNA segment was
digested with DraIII and SphI, inserted into the same sites of pUC19-G, and renamed
pUC19-H.
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The 1–5267 cDNA segment, digested with AatII and BstEII, was inserted into the
same sites of pACYC177 (NEB) and named p177-1Gen. The open reading frame of
EGFP was amplified by PCR using pEGFP (Clontech, Mountain View, CA) as the
template and the forward,
5’-TTGACTAGAAGGTCAAGAACCTGCAGGTCGACTCTAGAGGAT-3’, and
reverse,
5’-TTGACCTTCTAGTCAATGTCTTTAATCCTAAGTTTTTCTTATTTATTAACCG
GCGCTCAGTTGGAAT-3’, primers. Both primers contain a DrdI restriction site
(bolded) on their 5’ ends. The reverse primer also includes the HPIV-3 WT gene end,
intercistronic, and gene start signals (underlined). The 868 bp band was purified and
inserted into the SmaI site of pUC19, which was renamed pUC19-EGFP. pUC19-EGFP,
digested with DrdI, resulted in an 852 bp band that was inserted into the same site of
p177-1Gen and named p177-1Gen-E. A 1–6119 antigenomic cDNA segment, containing
EGFP, was digested out of p177-1Gen-E with PacI and BstEII, inserted into the same
sites of pUC19-F, and named pUC19-I. Finally, the 11284–15453 cDNA segment was
digested with DraIII and SphI, inserted into the same sites of pUC19-I, and renamed
pUC19-J.
Three PCR products encompassing the NP, P, and L genes were inserted into the
SmaI site of pUC19 and named pUC19-NP, pUC19-P, and pUC19-L. The following
three sets of forward and reverse primers were used: NP,
5’-GAAGGTCAAGAAAAGGGAACTCT-3’ and
5’-TTGATTCGATTAGTTGCTTCCA-3’; P, 5’-TGATGGAAAGCGACGCTAAA-3’
and 5’-GGATCATTGGCAATTGTTGA-3’; L, 5’-GCGTGCTCAGAAAATGGACA-3’
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and 5’-CCTTAGGCTTAAAGATAAAGGTTAGGA-3’. The start codon (bolded) for
the HPIV-3 WT accessory C protein, located on the P forward primer, was mutated from
T to C (underlined) to silence its expression. pUC19-NP, pUC19-P, and pUC19-L were
digested with SalI and KpnI and the 1.5, 2, 7 kb bands, respectively, were inserted into
the same sites of pTNT™ (Promega) and named pTNT-NP, pTNT-P, and pTNT-L.

2.4. Rescue of infectious virus from cDNA
HeLa cells, seeded in a 12-well plate, were infected with 5.4 x 105 plaque forming
units (PFU) of vTF7-3 at 1 multiplicity of infection (MOI) for 1 h. The virus and
medium were removed and replaced with Opti-MEM® (Invitrogen), containing 0.1 mM
NEAA. The three support plasmids, 0.8 μg of pTNT-NP, 1.6 μg of pTNT-P, and 0.04 μg
of pTNT-L, were cotransfected along with 0.4 μg of either pUC19-H or pUC19-J, using
Lipofectamine™ 2000 (Invitrogen) for 4-5 h at 37°C. MEM supplemented with 20%
FBS, 0.1 mM NEAA, 1 mM sodium pyruvate, and 250 μg/mL of Ara-C (Sigma) was
added to each transfection and incubated for 48 h at 37°C. The transfected cells were
scraped from the tissue culture wells and the lysates were frozen at -80°C. The rescued
rHPIV3, pUC19-H transfection, and rHPIV3-EGFP, pUC19-J transfection, viruses were
amplified on MA-104 cells, supplemented with 250 μg/mL Ara-C, for 3–4 days at 37°C.
The infected cells were scraped from the tissue culture wells and the lysates were frozen
at -80°C. Each virus was purified by picking agarose plugs over isolated plaques on
MA-104 cells in the absence of Ara-C. Each plug was placed in MEM and frozen at
-80°C. The medium, containing the plug and isolated virus, was used to infect MA-104
cells to amplify the virus for 3–4 days at 37°C. The purification and amplification steps
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were repeated two more times. The rHPIV3, rHPIV3-EGFP, and HPIV3 WT viruses
were amplified on MA-104 cells for 3 days at 37°C. The infected cells were scraped
from the tissue culture wells and the lysates were frozen at -80°C, which were used for
further testing. Sequencing of the 5’ ends of the genomic RNA, isolated from rHPIV3
and rHPIV3-EGFP infections, was repeated using the SMART™ RACE cDNA
Amplification Kit to confirm the DraIII genetic markers.

2.5. Viral infectious assays

2.5.1

Plaque assay
Duplicate dilutions of HPIV-3 WT, rHPIV3, and rHPIV3-EGFP, were used to

infect MA-104 cells in quadruplicate. Each virus was absorbed to MA-104 cells for 2 h,
after which, the virus was removed and replaced with an overlay of 1% SeaPlaque®
low-melting agarose (ISC BioExpress®, Kaysville, UT) supplemented with MEM and
0.2% sodium bicarbonate and incubated for 2–3 days at 37°C. Cells were fixed with
3.6% formaldehyde for 2 h at room temperature, after which, the formaldehyde and
agarose overlay was removed and 0.5% crystal violet was added for 5 min. After
removal of the dye and one rinse with phosphate buffered saline (PBS), the stained
plaques were counted. Viral titers were compared and statistically analyzed by unpaired,
two-tailed Student's t-test using the Microsoft® Office Excel 2003 software (Redmond,
WA). In addition, plaques produced by rHPIV3-EGFP were also photographed using an
Eclipse TS100 microscope (Nikon, Melville, NY), CoolSNAP digital camera, and RS
Image™ software, version 1.7.3, (both from Roper Scientific, Photometrics, Tucson, AZ).
Fluorescent photographs were taken with the same equipment except under UV light and
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the B-2A fluorescent filter combination was used, which incorporates excitation
wavelengths between 450 and 490 nm and emission filter wavelengths greater than 515
nm.

2.5.2

One-step growth curve
Duplicate 12-well plates were seeded with MA-104 cells and infected with 1.4 x

106 PFU of HPIV-3 WT, rHPIV3, and rHPIV3-EGFP viruses, separately, at an MOI = 2.
After the virus was absorbed to MA-104 cells for 2 h at 37°C, it was replaced with fresh
MEM supplemented with 2% FBS, and the cells incubated at 37°C. Individual wells
containing infected cells were scraped from the tissue culture wells and the lysates
harvested every 6 h starting at the time of virus exposure and frozen at -80°C. At time 0,
virus was added but then immediately removed and replaced with fresh medium. Each
time point for each virus was plaque titered in quadruplicate following the same method
as described above. Each growth curve was compared to the other two curves,
individually, and statistically analyzed by analysis of variance (ANOVA) using the
Microsoft® Office Excel 2003 software.

2.5.3

Cytopathic effect assay
Ninety-six-well plates were seeded with MA-104 cells and infected with 3.9 x 103

PFU of either the HPIV-3 WT or rHPIV3-EGFP virus in duplicate at an MOI = 0.1 in
quadruplicate wells. The plates were incubated at 37°C and on each day, including the
day of infection, the cells were stained with 0.034% neutral red for 2 h at 37°C, washed
once with PBS, and the NR extracted with ethanol:Sörenson’s citrate buffer for 30 min
while rocking at room temperature. Absorbances at 540 and 405 nm were read with an
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™

Opsys MR spectrophotometer equipped with Revelation Quicklink software, version
4.24 (both from Dynex Technologies, Chantilly, VA). The results were compared and
statistically analyzed by ANOVA.

2.5.4

QRT-PCR assay
Ninety-six-well plates were seeded with MA-104 cells and infected with 7.8 x 104

PFU of HPIV-3 WT and rHPIV3-EGFP viruses, separately, in duplicate at an MOI = 2.
At specific time points; 0, 12, 24, and 36 h, uninfected and infected cells were harvested
using CellsDirect Resuspension and Lysis Buffers (Invitrogen). Each lysate was used as
the template for two different reverse transcriptase (RT) reactions. One reaction used a
primer specific for the HPIV-3 genome,
5’-AATTATAAAAAACTTAGGAGTAAAG-3’, and the other reaction used an
Oligo(dT)20 primer (Invitrogen). The primers used to PCR amplify the cDNA products
from the RT reactions include 5’-CGTTATAGTGCTGCCACAAAGAATAA[FAM]G-3’
and 5’-ATGGAAGACCAGACGTGCATC-3’, for genomic replication, and
5’-CGATTAAGGAAAGCGACCTGTAAGTAAT[FAM]G-3’ and
5’-GAGACACAAATTAGGCGGGAGAT-3’, for L gene transcription. Platinum®
Quantitative PCR SuperMix-UDG (Invitrogen), 200 nM of the forward and reverse
LUX™ primers (Invitorgen), and 1/10th of the RT reaction were mixed and added, in
triplicate, to Hard-Shell 96-well skirted PCR plates (Bio-Rad Laboratories, Hercules,
CA). The reaction was run on a DNA Engine Opticon 2 Real-Time PCR Detection
System (MJ Research, Waltham, MA). The Opticon Monitor™ software, version 3.1.32
(Bio-Rad Laboratories), was used to calculate relative expression differences, Delta-CT,
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at each time point for each virus, using the 0 h for each virus as the baseline calibrator
(Pfaffl, 2001). For each assay, the two curves were compared and statistically analyzed
by ANOVA.

2.6. Antiviral sensitivity assay
An antiviral CPE assay was used to evaluate the antiviral sensitivity profiles of
the HPIV-3 WT and rHPIV3-EGFP viruses (Barnard et al., 2001; Cavanaugh et al.,
1990). Briefly, three compounds: ribavirin (positive control), 2-thio-6-azauridine, and
DAS181, were plated in four 10-fold dilutions in five replicates on 96-well plates seeded
with MA-104 cells using starting concentrations of 1000, 100, and 1 μg/mL, respectively.
Two of five replicates were toxicity controls with no virus added, while the other three
replicates were infected with 3.9 x 103 PFU of either the HPIV-3 WT or the
rHPIV3-EGFP virus at an MOI = 0.1. The plates were incubated at 37°C for 7 days and,
after which, the cells of each plate were stained with NR following the same method as
described above. The assays were completed three times. Fifty percent effective
concentrations (EC50) were calculated by linear regression using percents of untreated,
uninfected cell and untreated, infected virus controls. EC50 values were compared and
statistically analyzed by the unpaired, two-tailed Student's t-test.

2.7. EGFP expression assays
Ninety-six-well plates were seeded with MA-104 cells and infected with 3.9 x 104
PFU of rHPIV3-EGFP in duplicate at an MOI = 1. On each plate, quadruplicate four
10-fold dilutions of virus were plated and the cultures incubated at 37°C. Each day for 8
days, including the day of infection, the medium was removed and the cells were washed
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with PBS once and fresh PBS added. On the day of infection, the virus was added but
then immediately removed and the cells washed with PBS. EGFP fluorescence was
measured with the FMax® fluorometer, using the 485 nm excitation and 538 nm emission
filters, and recorded with SOFTmax® PRO software, version 1.3.1, (both from Molecular
Devices, Union City, CA).
Duplicate 96-well plates were seeded with MA-104 cells. On each plate, 16 wells
were infected with 3.9 x 103 PFU of rHPIV3-EGFP at an MOI = 0.1, while 16 wells were
left uninfected as a cell control and 16 wells were left unseeded as a no-cell background
control. The plates were incubated for 3 days at 37°C. After incubation, the uninfected
and infected cells and unseeded wells were washed with PBS, replaced with fresh PBS,
and fluorescence was measured using the FMax® fluorometer. The traditional NR-based
assay and Vybrant® MTT Cell Proliferation Assay (Invitrogen) were completed following
the same 96-well plate format mentioned above, except that each assay was conducted
after complete infected cell lysis on day 7. The cells for the NR assay were stained
following the same procedure described earlier, while the manufacture’s quick protocol
was followed for staining of the cells for the Vybrant® MTT assay. The absorbance
values for cells treated with MTT were measured at 540 nm, Opsys MR™
spectrophotometer, and Revelation Quicklink software. The CellTiter-Glo® Luminescent
Cell Viability Assay (Promega) was also performed using the same 96-well format except
that MA-104 cells were seeded on white, half area 96-well plates with a clear bottom.
Therefore, plating volumes were reduced by 50% and the CellTiter-Glo® reagent was
reduced by 75%, while otherwise following the manufacture’s protocol. Luminescence

62
was measured using the Centro LB 960 luminometer and recorded with MikroWin 2000
software, version 4.34 (both by Berthold Technologies, Oak Ridge, TN).

2.8. EGFP-based antiviral assay
Six 96-well plates were seeded with MA-104 cells to evaluate the NR and EGFP
assays in parallel. A format was used allowing seven compounds to be tested per plate.
Each compound was plated using four 10-fold dilutions in triplicate starting at 1000
μg/mL for ribavirin (positive control) and ribamidine; 100 μg/mL for 2-thio-6-azauridine,
3-deazaguanosine, 1-(4-methoxybenzyloxy) adenosine, selenazofurin, and EICAR; 100
μM for CS-978, CS-1164, CS-1196, CS-1227, PSI-0194, PSI-5067, PSI-5095, PSI-5098,
PSI-5452, PSI-5449, PSI-5741, PSI-5746, PSI-5747, PSI-5852, and PSI-5990; and 1
μg/mL for DAS181. Compounds that were reconstituted in dimethyl sulfoxide (DMSO)
were diluted down to working concentrations of 0.5 % or less DMSO to eliminate cell
toxicity due to the DMSO. Two of the replicates were infected with 3.9 x 103 PFU of
rHPIV3-EGFP, at an MOI = 0.1, while the remaining replicate served as a toxicity
control with no virus added. Three of the plates were incubated at 37°C for 3 days, after
which, the toxicity and cell control cells were stained with NR following the same
procedure described earlier. NR fluorescence was measured with the FMax®
fluorometer, using the 544 nm excitation and 612 nm emission filters. The untreated
virus control and treated, infected cells were washed with PBS, fresh PBS was added, and
the fluorescence measured with the FMax® fluorometer, using the 485 nm excitation and
538 nm emission filters. The other three plates were assayed using the traditional
colorimetric NR assay. After incubation for 7 days at 37°C, the cells were stained with
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NR following the same procedure described earlier. For the NR assay, EC50 and 50%
cell inhibitory concentrations (IC50) were calculated by linear regression from percents of
untreated, uninfected cell and untreated, infected virus controls. For the EGFP assay,
EC50 values were calculated by linear regression using percents of untreated, infected
virus controls and IC50 values were also calculated by linear regression using percents of
untreated, uninfected cell control. The EC50 and IC50 values for each compound for both
assays were compared and statistically analyzed by unpaired, two-tailed Student's t-test.
An SI was calculated for each compound for each assay using the formula: SI = Mean
IC50/Mean EC50. Compounds were sorted into positive, SI≥10, and negative, SI<10,
categories for the combination of NR and EGFP assays. Using the NR assay as the gold
standard, sensitivity, true positives/(true positives+false negatives), and specificity, true
negatives/(true negatives+false positives), were calculated.

3. Results

3.1. The successful insertion of the EGFP
gene into the HPIV-3 antigenome and
rescue of an infectious, recombinant
HPIV-3 expressing the fluorescent
protein
A DrdI restriction site was found between the N gene’s start signal and start
codon of the HPIV-3 WT antigenome that was used to facilitate the insertion of the
EGFP gene. Therefore, both the forward and reverse primers that were used to amplify
the EGFP open reading frame were designed to contain a DrdI restriction site on their 5’
ends. The HPIV-3 WT gene end, intercistronic, and gene start signals were also encoded
onto the reverse primer so that the inserted EGFP gene would be recognized as an
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additional HPIV-3 WT gene (Fig. 3-1A). The “Rule of Six” was followed to generate an
852 bp EGFP gene segment. The rule suggests that viral replication is most efficient
when the viral genome length is a factor of six ribonucleotides, which is most likely due
to a single nucleocapsid protein binding to six genomic ribonucleotides (Calain and
Roux, 1993; Durbin et al., 1997). In constructing the recombinant HPIV-3 expressing
EGFP, the presence of three G ribonucleotides, which are equally separated by five
ribonucleotides starting 79 ribonucleotides from the 5’ end of the antigenome, had to be
manipulated. This location represents one complete turn of the 3-dimensional helical
structure of the nucleocapsid encased RNA genome and is thought to co-regulate viral
replication perhaps through the assembly and binding of the viral polymerasephosphoprotein complex with the nucleocapsids (Tapparel et al., 1998). The EGFP
forward primer interrupted this natural pattern but the problem was solved by adding the
three G residues in the forward primer at positions 11, 17, and 23. Before the addition of
the EGFP gene segment into the antigenome, the 1–5267 cDNA segment was cloned into
the pACYC177 plasmid to circumvent multiple DrdI restriction sites located in the
pUC19 plasmid. The resulting 1–6119 cDNA segment, now encoding the gene for
EGFP, was then cloned into the pUC19 plasmid, already containing the 5249–11366
cDNA segment. Finally, the addition of the 11284–15453 cDNA segment to the
construct resulted in a complete, infectious, recombinant HPIV-3 virus, expressing the
EGFP gene.
To demonstrate the successful rescue and isolation of two rHPIV3 strains, one
with and one without the EGFP gene insertion, sequences surrounding three genetic
markers were aligned and compared to the HPIV-3 WT virus, isolate 14702 (Fig. 3-1B).
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Fig. 3-1. EGFP inserted into the rHPIV3 viral antigenome as the first gene. (A) The
EGFP PCR product was inserted into a natural DrdI site located between the N gene’s
start signal and start codon. T7/le indicates that a T7 promoter precedes the rHPIV3 5’
antigenomic leader sequence. tr/Rib indicates a hepatitis delta ribozyme immediately
follows the rHPIV3 3’ antigenomic trailer sequence. (B) Sequence data showing three
intentional mutations and recombinant markers: A to G, destroying a natural SphI site (*
indicating destroyed) located in the 5’ noncoding region of the L gene (A), and A to C
and T to G, creation of a unique DraIII site located within the 3’ trailer region (A). (C)
Electrophoresis of PCR fragments from HPIV-3 WT (1), rHPIV3 (2), and rHPIV3-EGFP
(3) digested with SphI.

RNA isolated from rHPIV3-EGFP, rHPIV3, and HPIV-3 WT infections was amplified
by RT-PCR. The sequences generated from the 5’ rapid amplification of cDNA ends
(RACE) RT-PCR, containing the DraIII restriction site, confirmed the A to C and T to G
mutations. These two mutations created a unique DraIII restriction site present only in
the recombinant viruses and allowed for the insertion of the final 11284–15453 cDNA
segment and completion of the recombinant viruses. The third genetic marker was also
confirmed by aligning sequences generated from the 5’ end of the L gene from all three
viruses. The A to G mutation eliminated one of two natural SphI restriction sites located
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in L gene portion of the HPIV-3 WT virus. The second SphI restriction site was used to
insert both the 5249–11366 and 11284–15453 cDNA segments. These PCR products
were also digested with SphI and separated on an agarose gel to show that HPIV-3 WT
was digested in the presence of SphI, while the two recombinant viruses were not (Fig.
3-1C).
Plaques formed by rHPIV3-EGFP were stained with crystal violet and analyzed
by bright field microscopy. The viral induced syncytia absorbed more crystal violet
compared to surrounding uninfected cells (Fig. 3-2A). The syncytia from the same
plaque were visualized by fluorescent microscopy and had high concentrations of green
fluorescence (Fig. 3-2B). On the other hand, plaques formed by HPIV-3 WT did not
produce fluorescence, data not shown. This result demonstrates a direct correlation
between viral growth, syncytia formation, and EGFP expression.

3.2. rHPIV3-EGFP replication is slightly
attenuated due to the additional gene
The infectious virus present in the stocks of all three viruses was plaque titered
and the means, ± standard deviation, of duplicate assays were found to be: 2.9 ± 0.41 x
107 PFU/mL for HPIV-3 WT, 2.8 ± 0.22 x 107 PFU/mL for rHPIV3, and 1.9 ± 0.49 x 107
PFU/mL for rHPIV3-EGFP. The infectious virus titer for rHPIV3 was not significantly
different compared to HPIV-3 WT whereas, rHPIV3-EGFP was significantly lower
compared to both HPIV-3 WT and rHPIV3 (p<0.01). The addition of the EGFP gene
into the HPIV-3 antigenome appeared to attenuate rHPIV3-EGFP compared to either the
WT or recombinant strains. However, the process of creating and rescuing the
recombinant virus and/or the presence of the three genetic markers did not cause
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Fig. 3-2. MA-104 cells showing an rHPIV3-EGFP induced plaque. (A) Plaque stained
with crystal violet and photographed under bright field microscopy. (B) Same plaque
photographed under fluorescent microscopy. Scale bar, 50 µm.
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attenuation of rHPIV3 because no significant reduction in virus titer was seen. For all
subsequent experiments the volume of virus inocula were adjusted so that equal PFUs
were added. In addition, the replication kinetics of the three viruses, HPIV-3 WT,
rHIPV3, and rHPIV-EGFP were measured to confirm the attenuation of rHPIV3-EGFP
compared to the wild-type and recombinant viruses. The growth curves for rHPIV3 and
HPIV-3 WT were very similar, with no significant differences (Fig. 3-3A). However, the
growth curve for rHPIV3-EGFP was significantly delayed compared to the growth curves
for both HPIV-3 WT and rHPIV3 (p<0.01). During the initial stages of infection, the
attenuated growth of rHPIV3-EGFP compared to both the wild-type and recombinant
viruses can be seen, yet it appears that the replication of the rHPIV3-EGFP virus may
recover and amplify itself to similar levels compared to the other two viruses during the
later stages of replication. This result confirmed that the addition of an additional gene
into the HPIV-3 genome may be the cause of attenuation.
The CPE produced by rHPIV3-EGFP and HPIV-3 WT viruses in infected
MA-104 cells was monitored for 7 days and measured by NR uptake until complete
infected cell lysis occurred, verified by microscopic examination. Complete cell lysis
induced by both viruses occurred at the same time on day 7 and no significant difference
in either curve was detected (Fig. 3-3B). This result contradicted previous results
showing attenuation in the replication of the rHPIV3-EGFP virus, but the result supports
the idea that rHPIV3-EGFP is able to recover and replicate up to HPIV-3 WT standards.
To determine how the additional gene may have contributed to the attenuation
seen during the onset of infection, a QRT-PCR assay was completed to measure genomic
replication and L gene transcription. An HPIV-3 specific primer that annealed to the
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Fig. 3-3. Infectious assays comparing the recombinant HPIV-3 virus, expressing EGFP,
to the wild-type and recombinant viruses. (A) Single step growth curve. The growth
curve for rHPIV3 (▲) was not significantly different compared to the growth curve for
HPIV-3 WT (■), while the growth curve for rHPIV3-EGFP (●) was significantly
different compared to the growth curves for HPIV-3 WT and rHPIV3 (p<0.01). (B) Time
course of HPIV-3 WT (■) and rHPIV3-EGFP (●) induced CPE. No significant
differences were detected. Relative expression differences of HPIV-3 WT (■) and
rHPIV3-EGFP (●) for L gene transcription (C) and genomic replication (D) measured by
QRT-PCR. Significant reductions were seen in rHPIV3-EGFP genomic replication and L
gene transcription compared to HPIV-3 WT (p<0.01). All Y-axis values on all graphs
represent the mean ± S.D. of duplicate assays.
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intergenic sequence between the fusion and hemagglutinin-neuraminidase genes of the
viral, negative-sense RNA, only allowing binding to viral, genomic RNA rather than viral
mRNA or viral, positive-sense, antigenomic RNA, was used as a primer for the RT
reaction. An Oligo(dT)20 primer was used to prime the RT reaction for the L gene
transcription measurement, binding only viral mRNA and not viral genomic RNA.
Relative expression differences were calculated and normalized, using the 0 h for each
virus as the baseline calibrator, according to the calculations developed by Pfaffl (2001).
A calibrator was used to normalize the amount of mRNA transcripts or genomic copies
generated during the infections with the amount that was added at the time of infection
for each virus. L gene transcription (Fig. 3-3C) and genomic replication (Fig. 3-3D) were
significantly reduced in an rHPIV3-EGFP infection compared to the HPIV-3 WT
infection (p<0.01). The additional gene present in the HPIV-3 genome caused a
reduction in the amount of viral mRNA transcripts and genomic copies that are normally
generated in a WT infection.

3.3. rHPIV3-EGFP is slightly more
sensitive to antiviral compounds
To further study the consequences of the attenuation detected for rHPIV3-EGFP
replication, three known antiviral compounds that inhibit HPIV-3 were tested. The three
compounds include two nucleoside analogs, ribavirin and 2-thio-6-azauridine, and a
recombinant fusion protein between a sialidase catalytic domain and cell
surface-anchoring sequence, DAS181 (Malakhov et al., 2006). EC50 values, which are
the concentration of compounds that inhibit 50% of virus replication, were calculated for
each compound for both HPIV-3 WT and rHPIV3-EGFP viruses. The mean, ± standard

deviation, of three replicates were found to be: 35 ± 2.5 μg/mL and 19 ± 4.9 μg/mL for
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ribavirin, respectively; 1100 ± 58 ng/mL and 630 ± 75 ng/mL for 2-thio-6-azauridine,
respectively; and 53 ± 2.3 ng/mL and 13 ± 2.3 ng/mL for DAS181, respectively. The
rHPIV3-EGFP virus was significantly more sensitive to inhibition by these compounds
than was the wild-type virus (p<0.05). This supports the idea that the rHPIV3-EGFP
virus was attenuated.

3.4. Using EGFP expression as a measure
of viral infectivity leads to a faster and
more robust assay
To determine the earliest possible day that a potential EGFP-based assay could be
completed, EGFP expression by rHPIV3-EGFP was measured. The fluorescence emitted
from the viral expressed EGFP was measured each day in rHPIV3-EGFP infected
MA-104 cells at various MOIs of virus. EGFP expression rose in a dose-dependant
manner beginning at day 1, peaked on day 3 regardless of MOI, and leveled off thereafter
(Fig. 3-4). Even though, the infection at MOI = 1 resulted in the greatest fluorescence, a
large amount of fluorescence was still detected for the other three MOIs as well. The
infection at MOI = 0.1 was equivalent to the concentration of virus used in typical
antiviral assays, so this concentration of virus was used in further testing.
To compare the 3-day, EGFP-based assay to the traditional NR-based assay,
Vybrant® MTT Cell Proliferation, and CellTiter-Glo® Luminescent Cell Viability Assays,
the Z´-factors, signal-to-background, and signal-to-noise ratios were calculated (Table
3-1). The Z´-factor is a statistical calculation that assesses the quality of a
high-throughput screening assay and predicts the potential of the assay if the number of
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Fig. 3-4. EGFP expression curve. rHPIV3-EGFP infected at differing MOIs: 1 (♦), 0.1
(■), 0.01 (▲), 0.001 (●) and measured by fluorescence. All Y-axis values represent the
mean ± S.D. of duplicate assays.

samples were scaled up. Z´-factors were computed for each assay and compared using
two different fitness tables (Kraybill, 2005; Zhang et al., 1999). Ultimately, a higher
Z´-factor value means the assay is more robust when it is used in a high-throughput
format. The 3-day, EGFP-based assay, 0.83, proved to be more robust than the other
three 7-day assays: 0.70 for the NR-based assay, 0.73 for the CellTiter-Glo® Luminescent
Cell Viability Assay, and 0.50 for the Vybrant® MTT Cell Proliferation assay. According
to the fitness tables, the EGFP-based, NR-based, and CellTiter-Glo® Luminescent Cell
Viability Assays were all considered to be good to excellent assays. On the other hand,
the Vybrant® MTT Cell Proliferation assay was considered to be borderline
excellent/marginal on one table and at the recommended minimum level for the second
table. For the signal-to-background ratios, the EGFP assay, with a value of 241, again
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Table 3-1
Evaluation of the viral expressed EGFP detection method compared to three types of
viral CPE detection methods using the rHPIV3-EGFP virus.
3-Day Assay

7-Day Assay

Viral expressed
EGFP fluorescence

Colorimetric neutral
red uptake

CellTiter-Glo®
Luminescent Cell
Viability

Vybrant® MTT Cell
Proliferation

Z´-factora

0.83

0.70

0.73

0.50

Signal-to-background

241

65

6

7

Signal-to-noise

4057

301

59

60

a
The Z'-factor is a statistical calculation that assesses the quality of a high-throughput screening assay and predicts the
potential of the assay if the number of samples were scaled up.

proved to be superior showing excellent signal to background signal separation. The NR
assay, value of 65, resulted in good separation, whereas both the CellTiter-Glo®
Luminescent, value of 6, and Vybrant® MTT assays, value of 7, resulted in poor
separation of signal to background signal. In addition, the EGFP assay, with a
signal-to-noise ratio of 4057, again proved to be superior to the other three assays,
signal-to-noise ratios of: 301 for NR, 59 for CellTiter-Glo®, and 60 for Vybrant® MTT,
by showing excellent signal to background variability separation.

3.5. Comparison of a 7-day, NR-based
antiviral assay and a 3-day,
EGFP-based antiviral assay
To investigate the practicality of using rHPIV3-EGFP in an antiviral screening
assay, a panel of 23 antiviral compounds were selected that had shown antiviral activity
against HPIV-3 in past screens (data not shown). A standard 7-day, NR-based assay and
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a 3-day, EGFP-based assay, using the same virus stock, were compared in parallel using
23 compounds, which included 22 nucleoside analogs and the one fusion protein,
DAS181 (Table 3-2). An SI value ≤3 was considered not active, SI values between 4 and
9 slightly active, between 10 and 49 moderately active, and ≥50 highly active.
Compounds with SI values ≥10 dictated if an antiviral drug would be further evaluated in
additional assays. Using the threshold SI value of 10, the 3-day, EGFP-based assay had a
sensitivity of 100% and specificity of 54%, compared to the 7-day NR assay. Using the
7-day NR assay as the gold standard, six compounds were falsely identified as selective
inhibitors of virus replication using the rHPIV3-EGFP virus in the antiviral assay, which
led to the 54% specificity. These six compounds showed an increase in the SI value over
the threshold of 10 in the EGFP assay but under the threshold in the NR assay. Of these
six, PSI-5449 was not active in the NR assay but was moderately active in the EGFP
assay. An additional four, ribamidine, selenazofurin, PSI-5852, and PSI-5095, were
considered slightly active in the NR assay and moderately active in the EGFP assay. The
remaining compound, CS-1196 was considered slightly active in the NR assay and highly
active in the EGFP assay. A factor that contributed to the differences in selectivity
detected in each assay was the lack of toxicity found in cells exposed to compound in the
EGFP assay. The toxicity of a drug is determined by the concentration at which it is
lethally toxic to 50% of the cells present in the assay, termed IC50. No toxicity was
observed for all six compounds falsely identified as selective inhibitors in the EGFP
assay and the IC50 values for four out of the six compounds were significantly decreased
in the 7-day NR assay (p<0.05). The difference in toxicity was probably due to the
accumulation of toxicity during the 7-day incubation period of the NR assay. On the
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Table 3-2
Panel of antiviral compounds tested by the traditional 7-day, colorimetric, neutral red
uptake assay and 3-day, EGFP fluorescence assay using the rHPIV3-EGFP virus.
Continued on next page.
Compound Name

7-Day colorimetric neutral red uptake assay

EICARc
DAS181

c

PSI-5067

e

PSI-5452

e

2-Thio-6-azauridine
PSI-5746
CS-1164

c

e

e

Ribavirinc

EC50a

IC50a

SIb

0.81 ± 0.061

>100

>120

0.013 ± 0.0015

>1

>79

0.76 ± 0.032

36 ± 9.2

48

0.84 ± 0.14

27 ± 2.5

32

0.6 ± 0.095

17 ± 3.5

28

6.4 ± 0.46

>100

>16

6.7 ± 0.21

>94 ± 9.8

>14

20 ± 3.6

230 ± 92

12

PSI-5990

e

8.7 ± 1.8

>100

>11

PSI-5747

e

8.3 ± 2.3

>79 ± 18

>10

PSI-5852

e

9.9 ± 2.8

>76 ± 21

>8

4.9 ± 1.4

34 ± 7.2

7

57 ± 15

390 ± 20

7

13 ± 2.1

83 ± 4.2

7

c

Selenazofurin
Ribamidine
PSI-5095

c

e

e

0.5 ± 0.078

2.1 ± 1.1

4

PSI-5449

e

30 ± 8.2

>95 ± 9.2

>3

PSI-5098

e

46 ± 7

>100

>2

38 ± 4.2

58 ± 26

2

>31 ± 1.5

34 ± 3.5

1

>100

>100

0

>100

>100

0

>100

>100

0

>31

31 ± 1.2

0

CS-1196

CS-1227

e

3-Deazaguanosinec
PSI-0194
CS-978

e

e

PSI-5741

e

1-(4-methoxybenzyloxy)
adenosinec
a

Mean of three independent assays ± S.D.

b

SI = Mean IC50/Mean EC50.

c

µg/mL.
Significant difference compared to the EC50 or IC50 of the 7-day NR uptake assay
(p<0.05).
e
µM.
d
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Table 3-2 Continued

3-Day EGFP fluorescent assay
EC50

IC50

SI

0.35 ± 0.025d

>100

>280

0.011 ± 0.0024

>1

0.86 ± 0.059
0.76 ± 0.085
0.89 ± 0.13

d

>89

>100

d

>120

>100

d

>130

>100

d

>110

5.1 ± 0.68

>100

>20

10 ± 3.3

>100

>10

31 ± 2.1d

>1000d

>32

9.8 ± 1.9

>100

>10

>100

>15

6.8 ± 0.46
2.9 ± 0.97

d

3.5 ± 0.1

>100

68 ± 2.6
d

0.47 ± 0.017

34 ± 0

>35
d

>1000

6.6 ± 0.53

3.9 ± 0

>100

d

>29
d

>100

>15

>100

d

>210

>100

d

>15

d

>26

>100

>3

43 ± 2.5

>100

d

>2

21 ± 3.2d

>100d

>5

>100

>2

>100

>2

>100

>100

0

>41d

41 ± 2.5d

0

50 ± 4

d

43 ± 0.58

d
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other hand, when the rHPIV3-EGFP virus was measured by the EGFP fluorescent assay
the resulting EC50 values were significantly lower (p<0.05) for three out of the six drugs
compared to the NR assay. This result will also contribute to the higher selectivity
detected for these compounds in the EGFP assay compared to the selectivity of these
compounds evaluated in the NR assay. The combination of an increased IC50 and a
decreased EC50 undoubtedly increased the SI for these six compounds and falsely
suggested further evaluation, explaining the low specificity of the EGFP assay. Overall,
for most other compounds a trend is seen when an increase in the SI value was detected
in the EGFP fluorescent assay compared to the NR assay. In most cases, the increased SI
can be contributed to either a significant decrease in the EC50, significant increase in the
IC50, or a combination of both scenarios.

4. Discussion
The purpose of this study was to investigate the possibility of substituting
rHPIV3-EGFP for HPIV-3 WT in the initial screening of potential antiviral compounds.
First, attenuation of either the rHPIV3 or rHPIV3-EGFP, compared to HPIV-3 WT, was
studied to determine if loss of virulence had occurred due to either the assembly or rescue
of a recombinant clone or the addition of the EGFP gene. The rescued rHPIV3 virus has
three genetic mutations that made it distinguishable from HPIV-3 WT. Although these
three genetic markers were detected in the rescued virus, they did not attenuate the
recombinant virus. Two of these markers reside in the 3’ untranslated region of the
HPIV-3 antigenome and could have disrupted regulatory promoters to attenuated
rHPIV3; but they did not. On the other hand, the addition of the EGFP gene into the
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rHPIV3 virus, which increased the length of the viral genome by only 5% and added a
seventh, distinctive gene unit, did significantly attenuate the rescued rHPIV3-EGFP
virus. Even though the attenuation was statistically significant, only a 1.5-fold reduction
in rHPIV3-EGFP titers was seen. The attenuation may be of no significance because a
wild-type virus grown in varying cell culture conditions: the age of the cells, confluency
of the cell monolayer, variation in the media formulations, or incubation in other varying
conditions, may inhibit or accelerate virus replication. A 10-fold, or greater, reduction in
virus titer would indicate severe attenuation and would suggest that the new virus was
indeed biologically different than the wild-type strain. In support of this point, the CPE
produced by rHPIV3-EGFP was not significantly different compared to the CPE
produced by HPIV-3 WT throughout the duration of a viral infection. Although,
decreased viral titers and slower viral replication was detected for the rHPIV3-EGFP
virus, CPE produced by each virus remained the same.
The attenuation of rHPIV3-EGFP can be attributed to the combination of the
small increase in genome length and the addition of a foreign gene, which contributed to
the significantly reduced viral genomic replication and mRNA transcription. The viral
polymerase terminates and reinitiates transcription at each gene junction inconsistently,
resulting in a reduction of downstream gene transcription and expression in a gradient
fashion (Cattaneo et al., 1987; Homann et al., 1990). Thus, the first of six viral genes,
NP, should be expressed at significantly higher levels compared to the last gene, L.
Therefore, the insertion of the EGFP gene into the first viral gene position should result
in a reduction in mRNA transcription in all downstream viral genes due to the
inconsistency of the viral polymerase to reinitiate viral mRNA transcription. This
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phenomenon was confirmed when transcription of the L gene was reduced in the
rHPIV3-EGFP virus infection compared to the HPIV-3 WT virus infection. In addition,
genomic replication was also reduced, perhaps due to the overall decline in the
expression of necessary viral replication proteins. A significant reduction in viral
transcription could also lead to a reduction in translation of the viral transcripts. Overall,
less viral proteins would be available for replication purposes resulting in less efficient
viral replication. Thus, less virions would be assembled because of the reduction in viral
proteins and genomic RNA strands resulting in an attenuated virus. Furthermore,
ribavirin and 2-thio-6-azauridine inhibit inosine monophosphate dehydrogenase and
orotidine monophosphate decarboxylase, respectively, and can be classified as nucleoside
analogs, which may be incorporated into the viral RNA strands and interfere with further
protein translation and genome replication (De Clercq, 1993; Sidwell, 1996). The
reduced EC50 values are probably related to the reduction in mRNA transcription and
genomic replication; therefore, less compound is needed to incorporate into the RNA
strands and inhibit viral expression. On the other hand, DAS181 eliminates the host cell
receptor needed for viral entry and inhibits virion binding and fusion (Malakhov et al.,
2006). The reduced EC50 values are most likely due to the reduction in viable virions
produced by the attenuated virus; therefore, less compound is required to prevent virion
attachment. The consequence of a slightly attenuated virus is the possibility of a reduced
EC50 value, which may increase the SI value above the threshold of 10 and result in a
false positive, meaning that the same compound may not inhibit the wild-type virus as
much. This consequence is acceptable in the initial screening of a high-throughput assay
because the false positive compounds would be retested in the presence of the wild-type

80
virus and if they were true false positives they would be eliminated in the second round
of screening.
The potential of using a recombinant virus that expresses a reporter gene to
measure viral replication leads to the possibility of detecting the virus earlier in the assay.
Assays that use dyes or enzymes, like NR, Vybrant® MTT, and CellTiter-Glo®
Luminescent, are only measuring the health of a cell and for these assays to be most
accurate the maximum difference between signal and background needs to be achieved.
This occurs for these types of assays when the virus has completely lysed the infected
cell monolayer or when cell membranes have become non-functional. The length of time
needed to reach this point depends upon the virus. The virus used in this study, HPIV-3,
requires 7 days to achieve complete cell destruction at the MOI used. However, using an
assay that measures a viral expressed reporter gene, the incubation time is only limited to
when the reporter gene reaches acceptable or maximal signal-to-background ratio levels.
For rHPIV3-EGFP, EGFP expression is detectable 24 h post-infection and reaches its
peak at 3 days in a dose responsive manner. The characteristic syncytia formation of the
HPIV-3 virus might be the reason that abundant EGFP expression levels are achieved and
remain for 5 days after the maximum expression levels are reached. Even the lowest
dose of virus shown could potentially be used in the antiviral assay, but for the purpose of
this study we chose to use a concentration of virus that was equivalent to the
concentration of virus used in typical antiviral assays. The broad range of EGFP
detection possibilities, in both the length of time and concentration of virus, could
potentially be used in experiments that need more defined parameters.
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The 3-day, EGFP-based assay was evaluated for use in high-throughput assays
using Z´-factor analysis and other parameters. It had a good to excellent Z´-factor value
in addition to very high signal-to-background and signal-to-noise ratios. The Z´-factor
takes into account the variability of both the signal and background and the difference
between the signal and background. Thus, the virus-expressed EGFP gene is very
suitable for this type of assay because only the infected cells will fluoresce and any
background measurement seen is due to autofluorescence of the plate, medium, or cells,
which can be subtracted from the signal. On the other hand the NR, Vybrant® MTT, and
CellTiter-Glo® luminescent assays all measure any intact cells infected or not infected
with virus. This can be problematic if the virus does not lyse the cell monolayer
completely because the background measurements are raised, reducing the sensitivity and
validity of the assay. For example, the CellTiter-Glo® luminescent assay was very
susceptible to this phenomenon because even when the cells of the virus controls were
completely lysed, as determined visually, significant luminescence was measured when
compared to the no-cell control (data not shown), thus the poor signal-to-background and
signal-to-noise ratios for the luminescent assay.
When the 3-day, EGFP assay was evaluated with a panel of known inhibitors of
HPIV-3 WT replication, the assay resulted in excellent sensitivity and marginal
specificity. When the rHPIV3-EGFP virus was used in an antiviral assay and
fluorescence was measured, approximately an equal number of false positives and true
positives would have passed the initial round of antiviral drug screening. However, this
is of no concern because in the second round of antiviral drug testing, HPIV-3 WT virus
would be used with results being measured by the NR uptake assay. In addition, active
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compounds could also be further evaluated and validated by virus yield reduction assay
or modified plaque reduction assay (Barnard et al., 2004; Matrosovich et al., 2006).
Thus, the true, false positives would be detected and eliminated from the drug screening
process. It would be more of a concern if the sensitivity were marginal because that
would mean that false negative compounds would be eliminated from further testing.
However, some of the differences seen between the SI values determined from the
EGFP-based and NR-based assays were due to differences in drug toxicity measured at 3
and 7 days, respectively. The compounds in question seem to be less toxic on day 3 than
on day 7, which implies that the toxicity effects accumulate over time. In addition, cell
growth may be slowed leading to apparent cell growth inhibition due to depletion of
nutrients and acid build up in the medium after 7 days of incubation. These two
phenomena probably contributed to the apparent increase in toxicity as measured by the
IC50 values in the 7-day, NR assay. Furthermore, because of the additional factors
contributing to cell toxicity a more accurate assay for detecting cell toxicity is conducted
in follow-up studies for active compounds using rapidly-dividing MA-104 cells, which
are incubated for 3 days in the absence of virus and measured by NR uptake. In essence,
the 3-day, EGFP assay may be more accurate compared to the 7-day, NR assay for
measuring cell toxicity.
The development of the EGFP assay has increased the sensitivity and quality of
the antiviral assay, while shortening the duration and significantly decreasing, although
not completely eliminating, the time consuming and labor intensive nature of the NR dye
uptake assay. Overall, the use of the rHPIV3-EGFP virus in initial antiviral drug testing
reduces the amount of time needed to obtain results and may be beneficial when testing
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numerous compounds in a high-throughput format. These conclusions warrant the
replacement of the HPIV-3 WT virus with the rHPIV3-EGFP virus in initial antiviral
testing. Finally, additional research to improve the 3-day, EGFP assay might include
scaling-up to a 384-well plate format and the development of a non-green fluorescent dye
to replace NR in cell toxicity measurements.
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CHAPTER 4
RECOMBINANT, INFECTIOUS HUMAN PARAINFLUENZA TYPE 3
VIRUSES DEFICIENT IN EXPRESSION OF THE D DOMAIN OF THE
PD PROTEIN SHOW A REDUCTION IN VIRAL REPLICATION

Abstract
The HPIV-3 P gene contains an editing site that leads to the expression of the
viral proteins, P, PD, the putative W, and theoretical V proteins. In this study, a rHPIV3
cDNA clone was engineered to express a hexahistidine tag on all proteins expressed from
the P gene start codon through mRNA editing. The P, PD, and W proteins were
identified but the V protein was not detected. Also in this study, the involvement of the
D domain in viral replication and/or the host cell’s antiviral response was investigated by
rescuing two knockout rHPIV-3 viruses, rHPIV3-ΔES and rHPIV3-ΔD, which are
deficient in the expression of the D domain of the PD protein by separate mechanisms.
The growth kinetics of the two knockout viruses were attenuated, compared to the parent
virus, when each virus was replicated in both MA-104 cells and A549 cells. Also, a
significant reduction in viral mRNA transcription and genomic replication, suggesting
attenuation, was seen in both knockout viruses. In addition, cytokine expression from
A549 cells infected with either knockout virus was unchanged or reduced compared to
cells infected with the parent virus. These data suggest that the D domain may be
involved in some aspect of viral replication and likely not involved in the host cell’s
antiviral response.
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1. Introduction
All members of the Paramyxovirinae subfamily express additional accessory
proteins from the P gene by mRNA editing and/or ribosomal choice, in addition to the P
protein. The C proteins, expressed by the respiroviruses, are transcribed by ribosomal
choice, where the ribosome scans the mRNA bypassing the first start codon and initiates
translation at a second start codon further downstream. For HPIV-3, the start codon for
the C protein is approximately ten ribonucleotides downstream from the start codon of
the P protein (Galinski et al., 1986). On the other hand, viral fusion proteins are
expressed by mRNA editing, which occurs when non-templated G residues are added by
the viral polymerase at an editing site located in the middle of the P gene during viral
mRNA transcription. The result of mRNA editing is a pool of P gene mRNA with
differing G insertions and leads to the translation of fusion proteins with identical
N-terminal ends and different C-terminal ends. For HPIV-3, the proteins expressed by
mRNA editing are the P, PD, putative W, and hypothetical V proteins (Galinski et al.,
1992; Vidal et al., 1990).
The functions of the accessory proteins have been attributed to regulation of viral
RNA synthesis and/or inhibition of the host cell’s antiviral response. For example, the C
proteins are involved in both regulating viral RNA synthesis and counteracting the
antiviral response of the infected host cell. The titers of recombinant HPIV-3 and SeV
viruses, which are deficient in the expression of their C proteins, are restricted in cell
culture (Durbin et al., 1999; Kurotani et al., 1998). However, the specific aspect of viral
RNA synthesis is different for each virus. The SeV virus C protein regulates genomic
replication, whereas the HPIV-3 virus C protein regulates viral mRNA transcription
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(Cadd et al., 1996; Malur et al., 2004). In addition, the SeV C protein inhibits some
aspect of the RIG-1 signaling pathway, but not the MDA-5 signaling pathway, thus
preventing the primary antiviral response and IFN-β expression from the infected host
cell (Strahle et al., 2007). Also, the SeV C protein interferes with the secondary antiviral
response by binding and inducing ubiquitination of STAT1; leading to
proteosome-mediated degradation of STAT1 and inhibition of IFN signaling (Garcin et
al., 2002). The HPIV-3 C protein also interferes with the secondary antiviral response by
binding and preventing the phosphorylation and activation of STAT1 and, thus, inhibiting
IFN signaling (Malur et al., 2005).
Furthermore, the V protein works in concert with the C protein to inhibit the
primary antiviral response and IFN-β expression. The V protein is characterized by a
highly conserved C-terminal cysteine-rich domain that binds two zinc atoms to form a
zinc-finger structure (Paterson et al., 1995). It is expressed by most members of the
Paramyxovirinae, except for HPIV-3 and HPIV-1 (Paterson et al., 1995; Vidal et al.,
1990). Even though the cysteine-rich domain is not encoded anywhere within the
HPIV-1 genome, it is located in the HPIV-3 antigenome in the same reading frame as the
W protein downstream of 2 or 3 stop codons, depending upon the virus strain (Chapter 3;
Galinski et al., 1992; Matsuoka et al., 1991). The V proteins for most paramyxoviruses
inhibit the primary antiviral response by binding MDA-5 and, thereby, preventing
dsRNA binding and further signaling of the antiviral response and inhibiting IFN-β
expression (Andrejeva et al., 2004; Childs et al., 2007). Also, the MeV V protein
interferes with IFN-β expression by competing with IRF-7 for binding to and

phosphorylation by IKKα, which is common to both RIG-1 and MDA-5 signaling
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pathways (Pfaller and Conzelmann, 2008).
Although the HPIV-3 antigenome may contain the nucleotide sequence that
encodes for the cysteine-rich domain characteristic of the V protein, it is still unknown if
it is expressed. In the only study reporting research pertaining to the HPIV-3 V protein,
the D and V domains were silenced individually and simultaneously (Durbin et al., 1999).
No attenuation in viral titers was seen when the individual or simultaneous knockout
viruses were used in vitro or individually in vivo, but attenuation was seen when the
domains were silenced simultaneously in vivo. These data suggest that the D and V
domains were expressed as proteins and that they played a role in the host cell’s antiviral
response. More recently, the PD protein of HPIV-3, which is the fusion of the N-terminal
end of the P protein and the C-terminal D domain, was detected in vitro. Three nuclear
localization signals were identified within the PD protein that directed the intracellular
location of the PD protein to the nucleus (Wells and Malur, 2008). Alternatively, if
HPIV-3 does not express the V protein, then perhaps the PD protein, which is only
expressed by HPIV-3 and bovine (B)PIV-3, is expressed to replace the V protein during
the viral infection and interferes with the primary antiviral response to reduce IFN-β
expression. In this study, we investigated if the V protein is expressed from the start
codon of the P gene through the editing site. We also identified possible roles of the D
domain in the viral replication cycle by generating knockout viruses deficient in the
expression of the D domain of the PD protein
.
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2. Materials and methods

2.1. Cells and viruses
MA-104 were obtained from the ATCC (Manassas, VA) and maintained at 37°C
and 5% CO2 in MEM (Hyclone Laboratories, Logan, UT) supplemented with 10% FBS
(Hyclone Laboratories). Human lung epithelial carcinoma cells (A549) were obtained
from the ATCC and maintained at 37°C and 5% CO2 in Dulbecco's modified eagle's
medium (DMEM, Hyclone Laboratories) supplemented with 10% FBS. A recombinant
vaccinia virus that expresses the bacteriophage T7 RNA polymerase, vTF7-3 was
generously provided by Dr. Bernard Moss (Fuerst et al., 1986). During all assays,
MA-104 and A549 cells were incubated in MEM supplemented with 2% FBS and 50
µg/ml gentamicin (Sigma Chemical Company, St. Louis, MO).

2.2. Plasmid Construction
The nucleotide sequence that encodes six histidine amino acids was inserted into
the rHPIV3 antigenome immediately following the P gene start codon using the
QuikChange® XL Site-Directed Mutagenesis (Stratagene, La Jolla, CA) kit and the
previously reported 1–5267 cDNA segment (Chapter 3). The forward,
5’-CTCAATCAATAGAGAGTTGATGCATCACCATCACCATCACGAAAGCGATG
CTAAAAACTATC-3’, and reverse,
5’-GATAGTTTTTAGCATCGCTTTCGTGATGGTGATGGTGATGCATCAACTCTCT
ATTGATTGAG-3’, primers were also used in the reaction to insert the nucleotide
sequence for the hexahistidine tag, underlined, at position 1787. The resulting clone was
sequenced for accuracy and renamed pUC19-NT. Two additional clones were also
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engineered to eliminate the P gene editing site and silence the D domain of the PD
protein using pUC19-NT as the template and QuikChange® XL Site-Directed
Mutagenesis kit. The forward,
5’-CTTCAACACATCAAGAAGATGACAAAAGAGGGAAAGACTGGTTT-3’, and
reverse, 5’-AAACCAGTCTTTCCCTCTTTTGTCATCTTCTTGATGTGTTGAAG-3’,
primers were used to delete 18 nucleotides at positions 2495–2512 from the antigenome.
The clone was sequenced for accuracy and renamed pUC19-DS. Also, the forward,
5’-CAAAAGAATTAAAAAAGGGGGAAAAGTGAAAGACTGGTTTAAGAAATCA
AAAG-3’, and reverse,
5’-CTTTTGATTTCTTAAACCAGTCTTTCACTTTTCCCCCTTTTTTAATTCTTTTG3’, primers were used to mutate a single nucleotide from G to T, underlined, at position
2514. The resulting clone was sequenced for accuracy and renamed pUC19-SD. The
assembly of the complete antigenomes for each mutant clone was followed as previously
described and they were renamed pUC19-L, which included a hexahistidine tag,
pUC19-V, which destroyed the editing site, and pUC19-X, which silenced the D domain
of PD protein (Chapter 3).

2.3. Rescue of infectious virus from cDNA
MA-104 cells, seeded in a 12-well plate, were exposed to vTF7-3 for 1 h at 1 x
105 PFU, which equals to a MOI of 1. The virus and medium were removed and replaced
with Opti-MEM® (Invitrogen, Carlsbad, CA). Three support plasmids, 1 μg of
pTNT-NP, 2 μg of pTNT-P, and 0.05 μg of pTNT-L were cotransfected along with 0.5
μg of either pUC19-L, pUC19-V, or pUC19-X using Lipofectamine™ 2000 (Invitrogen)
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for 6 h at 37°C (Chapter 3). MEM supplemented with 2% FBS and 250 μg/mL of Ara-C
(Sigma, St. Louis, MO) was added to each transfection and incubated for 3 days at 37°C.
The transfected cells were scraped from the tissue culture wells and the virus lysates
frozen at -80°C. The rescued viruses, rHPIV3-NT by pUC19-L transfection, rHPIV3ΔES by pUC19-V transfection, and rHPIV3-ΔD by pUC19-X transfection, were
amplified in MA-104 cells supplemented with 250 μg/mL Ara-C for 3 days at 37°C. The
infected cells were scraped from the tissue culture wells and the virus lysates frozen at
-80°C. Each virus was purified by removing agarose plugs containing virus plaques in
MA-104 cells in the absence of Ara-C. Each plug was placed in MEM and frozen at
-80°C. The medium, containing the plug and isolated virus, was used to infect MA-104
cells to amplify the virus for 3 days at 37°C. The purification and amplification steps
were repeated one more time. The rHPIV3-NT, rHPIV3-ΔES, and rHPIV3-ΔD viruses
were amplified a final time in MA-104 cells for 3 days at 37°C. The infected cells were
scraped from the tissue culture wells and the virus lysates were frozen at -80°C until used
in each experiment. Viral genomic RNA was purified and sequenced to identify
mutations contained in the P gene using SuperScript® III First-Strand Synthesis
SuperMix (Invitrogen) and the 5’-GCAACACCAGATGATGAAGAAGA-3’ forward
primer for cDNA synthesis. The cDNA products were amplified using AccuPrime™ Pfx
SuperMix (Invitrogen), the forward primer, mentioned above, and the
5’-GGATTACACCAAGATTCTGCAATAG-3’ reverse primer, and the amplification
products were then sequenced.
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2.4. Western blot analysis
Twelve-well plates were seeded with MA-104 cells and infected separately with
one of the following viruses: rHPIV3-NT, rHPIV3-ΔES, or rHPIV3-ΔD, at an MOI = 0.1
(3 x 104 PFU). Each virus was absorbed to the cells for 2 h at 37°C; after which the
virus was removed and replaced with fresh MEM supplemented with 2% FBS. The
plates were incubated at 37°C for 2 days. Protein from each infection was extracted
using M-PER® Mammalian Protein Extraction Reagent and concentration was measured
using the colorimetric BCA Protein Assay Kit (both from Pierce, Thermo Fisher
Scientific, Rockford, IL). The assay was measured with a SpectraMax® Plus384
Spectrophotometer (wavelength 562 nm) and the data analyzed with SOFTmax® PRO
software, version 4.3 (both from Molecular Devices, Sunnyvale, CA). A mixture of 20
μg of each protein sample, NuPAGE® LDS Sample Buffer and Sample Reducing Agent
was heated at 70°C for 10 min (Invitrogen). The resulting mixtures were then loaded on
a NuPAGE® Novex® 4-12% Bis-Tris Gel (Invitrogen) and electrophoresed at 200V for
approximately 1 h in NuPAGE® MOPS SDS Running Buffer and Antioxidant
(Invitrogen). The proteins in the gel were transferred to nitrocellulose using the iBlot™
Dry Blotting System and Gel Transfer Stacks (Invitrogen). The unbound protein binding
sites on the nitrocellulose membrane were bound with SuperBlock® T20 (TBS) Blocking
Buffer (Pierce) for 1 h with rocking at room temperature. Hexahistidine tagged proteins
were detected by the following chemiluminescent procedure. The Monoclonal
Anti-polyHistidine-Peroxidase (Sigma) antibody (4 μg/mL) was incubated with the
nitrocellulose membrane for 1 h with rocking at room temperature. The membrane was
washed three times with Tris buffered saline (TBS) containing 0.05% Tween-20 (Pierce)
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for 5 min with rocking at room temperature. The antibody bound proteins were then
incubated with the SuperSignal® West Pico Chemiluminescent Substrate (Pierce) to
detect any chemiluminescence. The membrane was then photographed with the Image
Station 2000R camera using a 1 min exposure and the image was analyzed with the 1D
Image Analysis software (both from Eastman Kodak Company, New Haven, CT). The
1D Image Analysis software was also used to estimate the molecular weight of each band
in each lane by comparison to the BenchMark™ His-tagged Protein Standards
(Invitrogen).

2.5. MA-104 replication plaque assay
Two 48-well plates were seeded with MA-104 cells and infected separately with
10-fold dilutions of rHPIV3-NT, rHPIV3-ΔES, and rHPIV3-ΔD viruses and plated in
triplicate. Each virus was absorbed for 2 h at 37°C; after which the virus inocula were
removed and replaced with an overlay of 1% SeaPlaque® low-melting agarose (ISC
BioExpress®, Kaysville, UT) supplemented with 1X MEM (Invitrogen). The plates were
incubated for 2 days at 37°C to allow plaque formation. Cells were then fixed with 3.6%
formaldehyde for 2 h at room temperature. The formaldehyde and agarose overlays were
then removed and 0.5% crystal violet was added to each well and incubated for 5 mins at
room temperature. After removal of the dye and rinsing one time with PBS, the stained
plaques were counted. Viral titers were compared and statistically analyzed using
unpaired two-tailed Student's t-tests. The resulting titers of each virus were used to
calculate and adjust the volumes of virus inocula to equalize the PFU of each virus used
in all subsequent experiments.
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2.6. A549 replication plaque assay
Two 12-well plates were seeded with A549 cells and the cells were infected
separately with one of the following viruses: rHPIV3-NT, rHPIV3-ΔES, and
rHPIV3-ΔD, at an MOI = 0.1 (4.8 x 104 PFU). Each virus was absorbed to the cells for 2
h at 37°C. The virus was then removed, replaced with fresh MEM supplemented with
2% FBS, and incubated at 37°C for 3 days. The infected A549 cells were scraped from
the tissue culture wells and the virus lysates frozen at -80°C. Each virus was plaque
titered in triplicate, following the method described above, and comparisons were
completed using unpaired, two-tailed Student's t-tests. To verify if any reversions had
occurred in the genomic sequences of either knockout virus the viral genomic RNA was
amplified and sequenced following the methods described above and compared to the
parent virus.

2.7. MA-104 and A549 one-step replication
curves
Two 12-well plates were seeded with MA-104 and A549 cells separately and
infected with either rHPIV3-NT, rHPIV3-ΔES, and rHPIV3-ΔD viruses separately at an
MOI = 3 (9.1 x 105 PFU for MA-104 cells and 1.4 x 106 PFU for A549 cells). Each virus
was absorbed to the cells for 2 h at 37°C. The virus inocula were then removed, replaced
with fresh MEM supplemented with 2% FBS, and incubated at 37°C. The infected cells
were scraped from individual tissue culture wells at 2, 12, 24, and 48 h post virus
exposure and frozen at -80°C. Each time point for each virus was quantified by plaque
assay in triplicate as described earlier. Statistical comparisons of the MA-104 and A549
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growth curves were compared by two-factor ANOVA and pairwise multiple comparisons
were accomplished by Tukey's honestly significant difference tests.

2.8. MA-104 viral QRT-PCR assay
Three 96-well plates were seeded with MA-104 cells and infected separately one
of the following viruses: rHPIV3-NT, rHPIV3-ΔES, and rHPIV3-ΔD at an MOI = 3 (5.7
x 104 PFU). At 0, 12, 24, and 48 h post virus exposure, RNA from uninfected and
infected cells was harvested the using CellsDirect™ Resuspension and Lysis Buffers kit
(Invitrogen). RNA from each lysate was used as a template for two different RT
reactions using the SuperScript™ III CellsDirect™ cDNA Synthesis System kit
(Invitrogen). A primer specific for the HPIV-3 genome,
5’-AATTATAAAAAACTTAGGAGTAAAG-3’, was used in one reaction and an
Oligo(dT)20 primer (Invitrogen) was used in a second reaction. LUX™ primers
(Invitrogen) were used to PCR amplify the cDNA products from the RT reactions and
included 5’-CGTTATAGTGCTGCCACAAAGAATAA[FAM]G-3’ and
5’-ATGGAAGACCAGACGTGCATC-3’ primers for genomic replication, and
5’-CGATTAAGGAAAGCGACCTGTAAGTAAT[FAM]G-3’ and
5’-GAGACACAAATTAGGCGGGAGAT-3’ primers for L gene transcription. The
contents of the Platinum® Quantitative PCR SuperMix-UDG kit (Invitrogen), 200 nM of
the forward and reverse primers, and one-third of the RT reaction, described above, were
mixed. The reaction mixtures were then added to duplicate wells of Hard-Shell 96-well
skirted PCR plates (Bio-Rad Laboratories, Hercules, CA). The reaction mixtures were
incubated in a DNA Engine Opticon 2 Real-Time PCR Detection System (MJ Research,
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Waltham, MA). The Opticon Monitor software, version 3.1.32 (Bio-Rad Laboratories)
™

was used to calculate the relative expression differences, Delta-CT, at each time point for
each virus using time 0 for each virus as the baseline calibrator (Pfaffl, 2001). Data
points outside the median ± three times the interquartile range were eliminated from
further analysis. Statistical comparisons of the viral mRNA transcription and genomic
replication curves were compared by two-factor ANOVA and pairwise multiple
comparisons were accomplished by Tukey's honestly significant difference tests.

2.9. A549 cytokine ELISA
Three 24-well plates were seeded with A549 cells and infected separately with the
following viruses: rHPIV3-NT, rHPIV3-ΔES, and rHPIV3-ΔD at an MOI = 0.1 (3.5 x
104 PFU). Each virus was absorbed for 2 h at 37°C. The virus inocula were removed,
replaced with fresh MEM supplemented with 2% FBS, and incubated at 37°C for 24 h.
The tissue culture medium for the infected and uninfected wells was removed and stored
at -80°C. Cellular RNA was isolated from the monolayer from the same tissue culture
wells and used for the QRT-PCR as discussed and shown below. Cytokine levels present
in the tissue culture media were measured by enzyme-linked immunosorbent assay
(ELISA) using the VeriKine™ Human Interferon-Beta ELISA Kit (PBL InterferonSource,
Piscataway, NJ) to measure IFN-β levels secreted by A549 cells. The assay was
measured on a SpectraMax® Plus384 spectrophotometer (wavelength 450 nm) and the data
analyzed with SOFTmax® PRO software. IFN-β expressed from MA-104 cells infected
with rHPIV3-NT at an MOI = 0.1 (2.5 x 104 PFU) was also assayed for using the same
procedure and ELISA kit. A human multiplex cytokine array was used to measure the

expression levels of interleukin (IL)-1α, IL-6, IL-8, IL-10, IL-12p70, monocyte
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chemotactic protein (MCP)-1, macrophage inhibitory protein (MIP)-1α, MIP-1β,
RANTES, IFN-γ, tumor necrosis factor (TNF)-α, and eotaxin (EO) cytokines also present
in the same supernatants following the manufacturer’s protocol (Cytokine Research
Institute, Logan, UT). Chemiluminescence was measured with a Quansys imager and the
data analyzed with Q-view™ software, version 2.0 (both from Quansys Biosciences,
Logan, UT). Concentrations of the cytokines present in the tissue culture media were
determined either by linear or exponential regression analysis. Data points outside the
median ± three times the interquartile range for IFN-β and the median ± one and a half
times the interquartile range for all other cytokines were eliminated from further analysis.
The concentrations of each cytokine expressed from A549 infected and uninfected cells
were compared for significance using unpaired, two-tailed Student's t-tests.
2.10. A549 interferon-β QRT-PCR assay
The CellsDirect™ One-Step qRT-PCR kit (Invitrogen) was used to amplify
mRNA encoding the IFN-β and β-actin genes from total RNA isolated from infected and
uninfected A549 cells 24 h after virus exposure. FAM labeled forward primer (200 nM)
and unlabeled reverse primer (250 nM) for the IFN-β D-LUX™ Select Gene Expression
Assay (Invitrogen) along with JOE labeled forward primer (100 nM) and unlabeled
reverse primer (125 nM) for the β-actin Certified LUX™ Primer Set (Invitrogen) were
added to the QRT-PCR mixture. Also, an additional 1 unit of Platinum® Taq DNA
Polymerase (Invitrogen) and 3 mM of magnesium sulfate (MgSO4) was also added to the
QRT-PCR mixture. Following Dnase I treatment of the total RNA samples, one-quarter
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of each sample was added to duplicate wells of Hard-Shell 96-well skirted PCR plates.
The reaction mixtures were incubated in a DNA Engine Opticon 2 Real-Time PCR
Detection System. Opticon Monitor™ software was used to calculate the relative
expression of Delta-Delta-CT of IFN-β during each infection using β-actin as an internal
control and the IFN-β expressed in uninfected cells as the baseline calibrator (Pfaffl,
2001). Data points outside the median ± three times the interquartile range were
eliminated from further analysis. Relative expression levels for IFN-β for each virus
infection were compared and statistically analyzed using unpaired, two-tailed Student's
t-tests.

3. Results

3.1. The successful rescue of infectious,
recombinant HPIV-3 viruses
expressing a hexahistidine tag without
the D domain of the PD protein
The rHPIV3-NT parent clone was constructed to contain six codons, each of
which encoded a histidine amino acid, CAU or CAC, immediately downstream of the P
gene start codon. This addition created a hexahistidine tag on all proteins expressed from
the P gene start codon, which included the known P and PD proteins and an unidentified,
putative W protein. The nucleic acid sequence that encoded the hexahistidine tag was
added to the complete viral antigenome to contain a total of 18 nucleotides to conform to
the “Rule of Six.” The rule suggests that viral replication is most efficient when the viral
genome length is a factor of six ribonucleotides, which is most likely due to a single
nucleocapsid protein binding to six genomic ribonucleotides (Calain and Roux, 1993;
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Durbin et al., 1997). Two other knockout clones, also containing the hexahistidine tag,
were made to silence the expression of the D domain of the PD protein using two
different approaches. In the first approach, 18 nucleotides, following the “Rule of Six,”
were eliminated from the P gene of the rHPIV3-NT antigenome that surrounded the
editing site, which formed the rHPIV3-ΔES clone. In the second approach, a single
nucleotide was substituted to create a stop codon and silenced only the D domain of the
PD protein, which formed the rHPIV3-ΔD clone. Sequence analysis of genomic RNA
isolated from separate infections of the three rHPIV3 clones and converted to DNA
showed an intact editing site in the rHPIV3-NT clone, the elimination of the editing site
in the rHPIV3-ΔES clone, and a single substitution mutation in the rHPIV3-ΔD clone
(Fig. 4-1A).
In addition, the proteins expressed from these clones could be detected with an
anti-HIS antibody. The rHPIV3-NT clone, with no modification to the editing site,
should have expressed the two predicted proteins, P and PD, and any other possible
proteins that are expressed from the P gene start codon, for example the putative W
protein. Western blot analysis of the rHPIV3-NT infected cell lysates, probed with an
anti-HIS antibody, showed the presence of a P protein at 78 kilodaltons (kDa), the PD
protein at 50 kDa, and the W protein at approximately 36 kDa (Fig. 4-1B). Other
possible proteins expressed by rHPIV3-NT through the P gene start codon, namely the V
protein, were not detected by western blot. For infected cell lysates exposed to the
rHPIV3-ΔES clone, only a single band at 77 kDa representing the P protein with six
amino acids removed was detected; notably absent were the W and PD protein bands.
For rHPIV3-ΔD infected cell lysates two bands were detected; one at 78 kDa,
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Fig. 4-1. Nucleotide sequence and western blot analysis of the rHPIV3 parent type and
knockout strains. (A) Nucleotide sequences of the parent strain (rHPIV3-NT) and
knockout strains (rHPIV3-ΔES and rHPIV3-ΔD). They also contain the sequence
5’-CATCACCATCACCATCAC-3’ following the start codon for the phosphoprotein to
express a hexahistidine tag ( ). (B) Western blot analysis of MA-104 infected cell
lysates of rHPIV3-NT (1), rHPIV3-ΔES (2), and rHPIV3-ΔD (3). Arrows indicate
positions of hexahistidine tagged viral proteins.

representing the P protein, and a second band at 36 kDa, representing the W protein. No
PD protein band was detected in the rHPIV3-ΔD infected cell lysates. The relative
expression levels of the individual proteins produced by rHPIV3-NT could not be
compared to each other nor estimated because only cell lysates were analyzed. The P
protein is a structural protein and is packaged with virions that are released from the
infected cell into the cell culture medium. However, relative expression levels between
all three recombinant viruses were estimated and used as a guide to judge the
effectiveness of the mutations. The rHPIV3-ΔES clone expressed only the P protein
resulting in a dramatic increase in the intensity of the P protein band, 78 kDa (Fig. 4-1B).

103
During replication of the rHPIV3-ΔD clone, the PD protein was truncated to a size equal
to that of the putative W protein. The intensity of the W protein band, derived from the
rHPIV3-ΔD infected cell lysates, increased slightly although there was no change in the
intensity of the P protein band.

3.2. Attenuation of the knockout clones
rHPIV3-ΔES and rHPIV3-ΔD in
MA-104 and A549 cells
To compare the replication kinetics of the two knockout clones, each virus was
amplified in MA-104 cells and A549 cells. In MA-104 cells, peak titers for all three
recombinant viruses were measured by plaque assay. The titers of the infectious
rHPIV3-ΔES and rHPIV3-ΔD viruses were significantly attenuated when compared to
the parent strain rHPIV3-NT (p<0.001) (Table 4-1); virus titers were reduced by over
50%. On the other hand, the peak titers of rHPIV3-ΔES and rHPIV3-ΔD were not
significantly different when compared to each other. MA-104 cells have been shown to
be completely susceptible to an HPIV-3 infection resulting in 100% CPE, which is most
likely due to the lack of IFN-β expression (Chapter 3 and Appendix A). Thus, HPIV-3
replication in MA-104 cells progresses unchallenged and any differences seen in the
replication kinetics of the knockout viruses compared to the parent virus could be
attributed to the kinetics of virus replication. Therefore, the similar lower viral titers of
the two recombinant viruses not expressing the D domain of the PD protein, suggests that
the D domain may facilitate virus replication. Even though it would seem that the D
domain might not be necessary for virus replication, it may be needed for optimal and
efficient virus replication. In support of this, a similar trend in lower viral titers was seen
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for each virus when infecting A549 cells. The titers for rHPIV3-ΔES and rHPIV3-ΔD
were significantly attenuated compared to the titer for rHPIV3-NT (p<0.001) (Table 4-1).
The titers of the two knockout viruses were also significantly different from each other,
with the rHPIV3-ΔES virus being the most attenuated (p<0.001). A549 cells appear to be
a more restrictive cell line for supporting virus replication based on the significant
difference in the viral titers of rHPIV3-NT grown in A549 and MA-104 cells (p<0.001)
(Table 4-1), probably due to the fact that A549 cells express IFN-β (Fig. 4-4A and D).
Knockout virus titers were attenuated compared to the titer of the parent virus in A549
cells, suggesting that the D domain could facilitate viral replication and/or interfering
with the host cell’s antiviral response.
One-step viral replication curves were completed to further understand the
attenuation of infectious knockout virus production in both MA-104 and A549 cells. The
results resembled the titer results. The viral replication curves generated in MA-104 cells
demonstrate an attenuation of rHPIV3-ΔES and rHPIV3-ΔD in virus production when
compared to the replication curve for the parent virus rHPIV3-NT (p<0.001) (Fig. 4-2A).

Table 4-1
3-day titers of the rHPIV3-NT parent type and rHPIV3-ΔES and rHPIV3-ΔD knockout
viruses in MA-104 and A549 cells.
Virus

MA-104 Cells

A549 Cells
p-value
vs. NT

Titera

p-value
vs. ΔES

7

p-value
vs. NT

Titer
7

rHPIV3-NT

7.5 ± 0.5 X 10

rHPIV3-ΔES

3.6 ± 1.4 X 107 p < 0.001

3.4 ± 0.8 X 106 p < 0.001

rHPIV3-ΔD

3.7 ± 0.6 X 107 p < 0.001 p > 0.05

1.9 ± 0.4 X 10

a

Mean of duplicate independent assays ± S.D.

3.1 ± 0.4 X 10

p-value
vs. ΔES

7

p < 0.001 p < 0.001
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But no significant differences were observed in the viral production of the two knockout
viruses, rHPIV3-ΔES and rHPIV3-ΔD. In addition, the viral replication in A549 cells
was also significantly reduced for the two knockout viruses, rHPIV3-ΔES and
rHPIV3-ΔD, when compared to virus production of the parent virus rHPIV3-NT
(p<0.001) (Fig. 4-2B). In contrast to the finding for infected MA-104 cells, virus
replication of the two knockout viruses, rHPIV3-ΔES and rHPIV3-ΔD, was significantly
different in A549 cells (p<0.001). These results support the notion that the knockout
viruses are attenuated and suggest that the D domain facilitates the virus replication
process in either cell type or may interfere with the antiviral response produced by A549
cells.
In both the peak titer assay and one-step replication curve in A549 cells, the titer
of the rHPIV3-ΔES virus was significantly reduced compared to the titer of the
rHPIV3-ΔD virus (Table 4-1 and Fig. 4-2B). One possible explanation for this could be
that the rHPIV3-ΔD knockout virus, which has a single point mutation to silence the
expression of the D domain, is reverting itself back into an rHPIV3-NT-like virus and
expressing the D domain. This would lead to an increase in viral titers of rHPIV3-ΔD,
which occurs when it is compared to the titer of the rHPIV3-ΔES virus. However, when
the genomic RNA for the rHPIV3-ΔD virus, along with the other two viruses, was
isolated and sequenced, no changes in the original mutations were seen (data not shown).
In addition, when rHPIV3-ΔD was replicated in both MA-104 and A549 cells and
rHPIV3-ΔES was replicated in MA-104 cells, a consistent 50% reduction in viral titers
was detected (Table 4-1). In contrast, a full-log reduction in the viral titer of
rHPIV3-ΔES was observed in A549 cells. This suggests that the replication of
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Fig. 4-2. Single-step replication curves of the two knockout viruses compared to the
parent virus. Replication of the parent virus, rHPIV3-NT (♦), and knockout viruses,
rHPIV3-ΔES (■) and rHPIV3-ΔD (▲), in MA-104 cells (A) and A549 cells (B). All Yaxis values on all graphs represent the mean ± S.D. of duplicate assays.
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rHPIV3-ΔES was even more restricted in A549 cells and confirms that no back mutations
occurred in the rHPIV3-ΔD virus. This result might be explained by the absence of six
amino acids from the middle of the P protein in the rHPIV3-ΔES virus, which may be
necessary for a luxury function of the P protein. This phenomenon only occurred in the
restrictive A549 cells infected with the rHPIV3-ΔES virus and not in MA-104 cells.
Hence, the six amino acid deletion may have interfered with the host cell’s antiviral
response.

3.3. Viruses deficient in the expression of
the D domain show a reduction in
genomic replication and viral gene
transcription
To further investigate if the knockout viruses deficient in the expression of the D
domain of the PD protein are attenuated viruses, viral genomic replication and gene
transcription were measured by QRT-PCR at various time points during viral replication
in MA-104 cells. During the RT reaction, different primers were used to measure viral
gene transcription and genomic replication independently of each other. In both cases,
viral gene transcription and genomic replication were significantly reduced in both
knockout viruses rHPIV3-ΔES and rHPIV3-ΔD when compared to the viral RNA
synthesis of the parent virus rHPIV3-NT (p<0.001) (Fig. 4-3). On the other hand, no
significant differences were seen in viral gene transcription and genomic replication of
the two knockout viruses, rHPIV3-ΔES and rHPIV3-ΔD. These results not only support
the notion that the two knockout viruses are attenuated, but also that the D domain may
facilitate all aspects of viral RNA synthesis.
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Fig. 4-3. Viral RNA synthesis of the two knockout viruses compared to the parent virus
measured by QRT-PCR. Viral mRNA transcription (A) and genomic replication (B)
from the parent virus, rHPIV3-NT (♦), and knockout viruses, rHPIV3-ΔES (■) and
rHPIV3-ΔD (▲), in MA-104 cells. All Y-axis values on all graphs represent the mean ±
S.D. of triplicate assays.

109
3.4. A549 cells infected with viruses
deficient in the expression of the D
domain have decreased expression of
inflammatory cytokines
To investigate the other putative functions of the D domain, cytokine expression
in A549 cells infected with each knockout virus, rHPIV3-ΔES and rHPIV3-ΔD, was
measured and compared to cytokine expression of A549 cells infected with the
rHPIV3-NT parent virus. Time course evaluation of IFN-β expressed from A549 cells
infected with rHPIV-NT showed peak expression at 24 h, therefore cytokine expression
studies were measured at this time point (see Appendix A). Of the cytokines measured
by ELISA, only five cytokines, IFN-β, IL-6, IL-8, RANTES, and MCP-1, were
significantly increased from infected cells when compared to uninfected cell controls
(p<0.01) (Fig. 4-4A, B, and C). The expression levels of the cytokines IFN-β, IL-6 and
RANTES were significantly decreased in the cells infected with both knockout viruses
when compared to cells infected with the parent strain (p<0.01) (Fig. 4-4A and B). On
the other hand, the expression levels of the IL-8 and MCP-1 cytokines of A549 cells
infected with all three viruses were similar (Fig. 4-4B and C). To confirm the reduction
in IFN-β expression levels in cells infected with the knockout viruses, IFN-β mRNA
levels were measured by multiplex QRT-PCR. IFN-β mRNA levels were significantly
reduced in A549 cells infected with either knockout viruses when compared to the levels
of IFN-β transcribed in cells infected with the parent virus (p<0.05) (Fig. 4-4D). These
data confirm that the knockout viruses show attenuation and suggest that the D domain
may not be involved in the A549 cell’s antiviral response because of a reduction or no
change in cytokine expression.
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Fig. 4-4. Cytokine profile expression in infected A549 cells measured by ELISA and
QRT-PCR. Only the IFN-β (A), IL-6 (A), RANTES (B), IL-8 (B), and MCP-1 (C)
cytokines expressed from infected A549 cells resulted in significant increases compared
to uninfected cell controls (white bars, 4) (p<0.01). Significant decreases were seen in
the levels of cytokines expressed from A549 cells infected with either rHPIV3-ΔES (grey
bars, 2) or rHPIV3-ΔD (diagonal bars, 3) compared to cells infected with rHPIV3-NT
(black bars, 1) (
) (p<0.01). A significant increase was seen in the levels of the
IFN-β (A) and RANTES (B) cytokines expressed from A549 cells infected with
rHPIV3-ΔES compared to cells infected with rHPIV3-ΔD ( ) (p<0.01). (D) IFN-β
mRNA transcription, measured by QRT-PCR, in cells infected with either rHPIV3-ΔES
or rHPIV3-ΔD were significantly reduced compared to cells infected with rHPIV-NT ( )
(p<0.05). All Y-axis values on all graphs represent the mean ± S.D. of triplicate assays.
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As noted above, rHPIV3-ΔES virus titers in A549 cells were dramatically reduced
compared to not only the parent rHPIV3-NT virus titers, but more importantly the
rHPIV3-ΔD knockout virus. Levels of IFN-β and RANTES expression from A549 cells
infected with the rHPIV3-ΔES virus were significantly increased compared to the
cytokines expressed from A549 cells infected with rHPIV3-ΔD (p<0.01) (Fig. 4-4A and
B). However, IFN-β mRNA levels in cells infected with either knockout viruse were
transcribed at similar levels (Fig. 4-4D). These results may suggest that the six amino
acids deleted from the P protein of the rHPIV3-ΔES knockout virus may influence the
host cell’s antiviral response.

4. Discussion
One of the objectives of this study was to investigate the possibility of the
expression of additional proteins containing the N-terminal end of the P protein of
HPIV-3. The P gene contains an editing site where the viral RNA-dependent
RNA-polymerase stops and stutters adding non-templated G nucleotide residues
(Appendix B) (Galinski et al., 1992). These additions lead to a pool of P gene mRNA
with differing G insertions and three different C-terminal ends fused to an identical
N-terminal end. Adding the nucleotide sequence that encodes for a hexahistidine tag
immediately downstream of the start codon of the P gene would label the proteins
expressed from the P gene that share the N-terminal end. This would allow the
identification of the P and PD proteins and might identify the putative W protein and/or
the theoretical V protein (Galinski et al., 1986; Wells and Malur, 2008). The V protein is
expressed by all other members of the Paramyxoviridae family and is characterized by a
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conserved cysteine-rich domain that forms a zinc finger (Paterson et al., 1995). In HPIV3, this same domain, although semi-conserved, is also encoded for within the P gene in
the same reading frame as the W protein downstream of 2–3 stop codons, depending
upon the virus strain, thus allowing for the potential expression of the V protein (Galinski
et al., 1992). In this study using hexahistidine tags, the proteins found to be expressed
from the P gene start codon during an rHPIV3-NT infection were the P, PD, and W
proteins; no V protein was detected by western blot. According to the nucleotide
sequence, the calculated molecular weight of the P, PD, and W protein should be 68, 43,
and 28 kDa, respectively. However, the observed molecular weights in our study
appeared to be 78, 50, and 36 kDa, respectively. This discrepancy might be attributed to
high levels of phosphorylation and other post-translational modifications. Although no
band, representing the V protein, was detected, it could still exist at extremely low
expression levels that are beyond levels of detection. Low levels of expression could be
possible due to ribosomal frameshifts and/or readthrough mechanisms as seen in
retrovirus systems (Leger et al., 2007). In addition, the V protein could also be expressed
from a different initiation codon either by internal ribosome binding sites, which are
present in picornaviruses and hepatitis C viruses, or by ribosomal shunting exhibited by
adenoviruses and paramyxoviruses (Boehringer et al., 2005; Junemann et al., 2007;
Latorre et al., 1998; Xi et al., 2005).
To understand the fitness of a virus relative to various mutants of the parent virus,
measuring the titer of each virus could offer clues on the possible differences in the
replication cycles of the viruses or possible consequences of mutations. In this study, the
results from both the virus titration and viral replication curve assays suggest that the lack

113
of expression of the D domain from the PD protein results in an attenuated virus. When
the expression of the D domain was silenced in two different ways, the resulting
infectious viral titers of the two knockout viruses, rHPIV3-ΔES and rHPIV3-ΔD, were
significantly reduced compared to the parent virus rHPIV3-NT when grown in two
different cell lines, MA-104 and A549 cells (p<0.001). Since attenuation was observed
in both cell lines, A549 cells that express IFN-β and MA-104 cells that do not, the results
of this study suggest that the D domain is involved in some aspect of viral replication and
not necessarily involved in countering the host cell’s antiviral response. On the other
hand, if attenuation had been seen in A549 cells and not in MA-104 cells, that
observation would have suggested that the D domain of the PD protein played a role in
the countering the host’s cell antiviral response. The involvement of the D domain in
some aspect of viral replication is supported by the results that both viral genomic
replication and viral mRNA transcription from both knockout viruses were significantly
reduced when compared to the parent strain (p<0.001). By measuring both major viral
RNA synthesis processes, viral mRNA transcription and genomic replication, any
differences between the knockout viruses and the parent virus in either process would
suggest involvement of the D domain in that particular process. But, since a reduction
was detected in both processes, the function of the D domain may influence and/or play a
general role in viral RNA synthesis.
Durbin et al. (1999) published a study in which they also knocked out the D and
V domains encoded for in the P gene. In their study, they reported no attenuation in the
titers of the knockout viruses, deficient in the expression of the D and V domains
individually, in vitro or in vivo. But when the D and V domains were silenced
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simultaneously, they detected attenuation in the viral titers only in vivo. In contrast,
attenuation in viral titers was observed for both knockout viruses deficient in the
expression of the D domain in this study. The major difference between the two viruses
used in each study was the position of the stop codon in relation to the remaining sense
codons of the D domain. Durbin et al. (1999) introduced three stop codons into the
nucleotide sequence that encodes the PD protein at amino acid positions 304, 305, and
306. In the current study, only one stop codon was introduced into the nucleotide
sequence that encodes the PD protein at amino acid position 245, which immediately
follows the editing site located within the P gene. With the stop codon located
immediately following the editing site, it is ensured that the complete D domain is
silenced and that any differences seen, compared to the parent virus, can be attributed to
the D domain. In contrast, Durbin et al. (1999) introduced the stop codons in the middle
of the D domain. Therefore attenuation can only be attributed to the C-terminal end of
the D domain and not to the complete D domain. In addition, Wells and Malur (2008)
identified three total nuclear localization signals encoded in the PD protein, located at
amino acid positions 225–241, 266–272, and 340–346. From the results of these three
studies, it can be concluded that the deletion of both nuclear localization signals located
in the D domain of the PD protein results in an attenuated virus, but the deletion of the
nuclear localization signal at amino acid position 340–346 alone does not attenuate the
virus.
Although the attenuation of the knockout viruses deficient in the expression of the
D domain in A549 cells can be explained by a reduction in viral RNA synthesis it could
have also been attributed to an increase or decrease in the host cell’s antiviral response.
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An increase in cytokine expression levels from A549 cells infected by the knockout
viruses would have suggested that the D domain interfered with the host cell’s antiviral
response. Theoretically, cytokine expression levels would be reduced during a normal
infection when the viral D domain is expressed if the D domain interfered with the host
cell’s antiviral response. On the other hand, the absence of the D domain should have
allowed the host cell’s antiviral response to operate freely and an increase of cytokines
expressed from infected A549 cells would have been seen. Therefore, more cytokines
present would have induced greater control over virus replication by the infected cells
manifested by a reduction in viral titers. But in the current study, cytokine expression
levels of the knockout viruses were either significantly reduced or unchanged (p<0.01),
suggesting that the D domain does not perturb the host cell’s antiviral response, but
instead leads to an attenuated virus via viral RNA synthesis regulation. An attenuated
virus should induce a weaker antiviral response from infected cells resulting in reduced
cytokine expression because the host cells would need a less aggressive immune response
to control a weaker infection.
The host cell’s antiviral response can be initiated by intracellular uncapped
mRNA and/or dsRNA, which is detected by RIG-1 and MDA-5 (Hornung et al., 2006;
Kang et al., 2002; Kato et al., 2008; Pichlmair et al., 2006). RIG-1 and MDA-5, bound to
dsRNA, induce a cascade that leads to the dimerization and translocation of the
transcription factor IRF-3 into the nucleus, which initiates the expression of IFN-β and
RANTES (Au et al., 1995; Lin et al., 2000). Then it is no surprise that in this study, the
IFN-β and RANTES expression levels for all three RNA viruses were identical.
Whereas, an IRF-3 binding site located in the promoter region of MCP-1 and IL-6 has not
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been found, the IL-8 promoter does contain an IRF-3 binding site (Samuel et al., 2008;
Sutcliffe et al., 2009; Wagoner et al., 2007). Therefore, IL-8 should have also been
expressed from A549 cells infected with the three rHPIV3 viruses in a similar pattern
compared to IFN-β and RANTES in this study. Although, IL-8 is expressed as a result of
the presence of dsRNA and the IFN primary response, IFN-β induction of the Jak/STAT
signaling pathway leads to inhibition of IL-8 expression, among a multitude of other
pathways (Laver et al., 2008). This might explain why no significant difference in IL-8
expression was detected in A549 cells infected with any of the three viruses because IL-8
cytokine levels were being controlled by IFN-β expression.
Six amino acids, IKKGGK at position 238–243 of the P protein, were deleted
from the P protein in the rHPIV3-ΔES virus, which encoded a portion of a bipartite
nuclear localization signal, amino acid position 225–241 (Wells and Malur, 2008). The
replication kinetics of this knockout virus in A549 cells was further attenuated when
compared to the replication of the same virus in MA-104 cells. On the other hand, the
degree of reduction in viral titers of the rHPIV-ΔD knockout virus in both MA-104 and
A549 cells were similar. In contrast, an increase in the expression of the IFN-β and
RANTES cytokines induced from A549 cells infected with the rHPIV3-ΔES knockout
virus was detected when compared to the levels of RANTES and IFN-β detected in cells
infected with the rHPIV-ΔD knockout virus. Using the same logic mentioned previously,
these results might suggest that the nuclear localization signal, located on the N-terminal
side of the editing site in the P gene for the P, PD, and W proteins, is involved in
counteracting the host’s cell antiviral response in a new, novel way. The host cell’s
primary IFN-β response is initiated by dsRNA in the cytoplasm and finishes with the

117
translocation of cellular transcription factors to the nucleus and IFN-β expression.
Perhaps the nuclear localization signal present on the viral P, PD, and W proteins allows
the translocation of these viral proteins to the nucleus where their N-terminal ends
interact with host cell’s transcription factors and directly interfere with IFN-β expression.
However, the rHPIV3-ΔES virus is also deficient in the expression of the W
protein and that could also explain the further attenuation and increased induction of
cytokine expression in A549 cells infected with the rHPIV3-ΔES virus. The
contradicting results of different IFN-β protein expression levels and similar IFN-β
mRNA transcription levels of the two knockout viruses in A549 cells, might suggest that
the W protein may influence cellular protein synthesis. Both cellular and viral protein
synthesis occur in the cytoplasm and the translational machinery is used concurrently by
both entities. Thus, it would not be out of the realm of possibility that HPIV-3 might
encode a viral protein that “hijacks” a component of the host cell’s protein synthesis
machinery to preferentially promote viral protein synthesis. In the absence of the W
protein, an increase in cellular protein expression would be seen. In addition, cellular and
viral mRNA transcription are separate processes that occur in different compartments of
the cell. Therefore, cellular mRNA transcription may not be directly influenced by the
viral replication machinery and no change in cellular mRNA transcription would be seen
in the absence of the W protein. Even though, this theory is supported by the significant
difference in IFN-β protein expression (p<0.01) and no difference in mRNA transcription
between the knockout viruses, a majority of the amino acid sequence representing the W
protein is also present in the P protein. Therefore, the W protein’s function could be
present and active, even though no 36 kDa W protein is directly expressed by the
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rHPIV3-ΔES virus. In addition, if the W protein did influence cellular protein expression
a more dramatic difference in viral titers may have been detected in the replication of
rHPIV3-ΔES in MA-104 cells, similar to the full-log reduction in viral titers detected in
A549 cells. Overall, a combination of the two processes, direct interference with IFN-β
expression or the viral W protein “hijacking” the host cell’s translational machinery,
might explain the differences in cytokine expression and viral titers in A549 cells
observed between the two knockout viruses in the current study.
In summary, three proteins, P, PD, and W, were found to be expressed from the P
gene start codon within the HPIV-3 genome, but expression of the V protein from the
same start codon was not detected. Also, the lack of expression of the D domain from
two knockout viruses resulted in a reduction in viral genomic replication and viral mRNA
transcription. In addition, the unchanged or reduced extracellular levels of cytokines
expressed from A549 cells infected with each knockout viruses confirms the notion that
the D domain may be involved in viral RNA synthesis rather than negatively perturbing
the host cell’s antiviral response. The PD protein contains three nuclear localization
signals and has been localized to the cellular nucleus (Wells and Malur, 2008). The main
functions occurring in a cell’s nucleus are cellular mRNA transcription and cellular
genomic DNA replication with an abundance of protein-nucleic acid complexes and
co-factors involved with each process. Therefore, the PD protein may enter the nucleus
to recruit necessary cellular proteins and/or co-factors to aid in viral RNA synthesis
occurring in the cytoplasm. For example, the cellular La protein, which is responsible for
cellular RNA protection and mainly found in the nucleus, has been found to bind the
single-stranded genomic RNA of RSV (Bitko et al., 2008; Rinke and Steitz, 1982). The

119
HPIV-3 PD protein may recruit the cellular La protein to bind to the single-stranded
genomic RNA of HPIV-3 for protection and increase the efficiency viral RNA synthesis.
Further research is needed to investigate why the PD protein needs to translocate
to the nucleus and to identify what cellular and/or viral proteins the PD protein interacts
with to promote viral RNA synthesis. In addition, the bipartite nuclear localization
signal, which is present on the N-terminal end of the P, PD, and W proteins, needs to be
further studied to determine what role it plays in the viral replication cycle by
counteracting the host cell’s antiviral response.
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CHAPTER 5
SUMMARY

The purposes of this study were to develop a high-throughput antiviral assay and
investigate the function of the D domain for HPIV-3 using reverse genetics. The two
main focuses of the current study were the insertion of the foreign EGFP gene into the
viral antigenome and silencing the expression of the D domain. Reverse genetics
techniques were used to successfully construct an rHPIV3 cDNA clone that was
amplified directly from viral genomic RNA isolated from an HPIV-3 WT infection. The
rHPIV3 cDNA clone was then used as a backbone for genetic manipulation during each
phase of the current study. In the first phase, the gene encoding for EGFP was inserted
into the rHPIV3 antigenome, rHPIV3-EGFP, upstream of the NP gene’s start codon;
therefore EGFP was expressed as the first gene. In the second phase, two rHPIV3 clones
were engineered to be deficient in the expression of the D domain, in unique
mechanisms. In one clone, 18 nucleotides surrounding the editing site in the P gene were
removed, rHPIV3-ΔES, and in the second clone, a single ribonucleotide was changed to
create a nonsense mutation that silenced the expression of the D domain, rHPIV3-ΔD.
In both phases of the current study, the replication of the altered rHPIV3 viruses
were significantly attenuated in the permissive MA-104 cell line compared to their
respective parent viruses, HPIV-3 WT from which rHPIV3-EGFP was derived and
rHPIV3-NT from which rHPIV3-ΔES and rHPIV3-ΔD were derived. In addition, both
viral genomic replication and viral mRNA transcription were also significantly reduced
in MA-104 cells infected with the rHPIV3-EGFP, rHPIV3-ΔES and rHPIV3-ΔD viruses
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compared to their respective parent viruses. These results suggest that the presence of the
additional EGFP gene in rHPIV3-EGFP and the silenced expression of the D domain in
both rHPIV3-ΔES and rHPIV3-ΔD may have negatively influenced all aspects of viral
RNA synthesis, which led to the attenuation.
Furthermore, the rHPIV3-EGFP virus was evaluated for use in antiviral assays as
a substitute for HPIV-3 WT. The time frame to complete an antiviral assay for HPIV-3
WT in MA-104 cells is approximately seven days and both viruses exhibited similar
amounts of CPE, measured by NR dye uptake, when compared to each other over that
same 7-day time frame. In addition, the expression of EGFP in MA-104 cells infected
with rHPIV3-EGFP peaked at three days, which would allow for a more efficient and
quicker assay if the rHPIV3-EGFP virus is to be used in an antiviral assay. To further
test the fitness of the EGFP fluorescent assay the Z´-factor, signal-to-background, and
signal-to-noise ratios were measured and compared to three other 7-day cell fitness
assays, NR dye uptake, CellTiter-Glo® Luminescent Cell Viability Assay, and Vybrant®
MTT Cell Proliferation assay. When the scores for Z´-factor, signal-to-background, and
signal-to-noise were compared between all four detection assays, the 3-day viral
expressed EGFP fluorescent assay was more robust and superior to the other three 7-day
indirect CPE detection methods.
When the HPIV-3 WT and rHPIV3-EGFP viruses were replicated in MA-104
cells and exposed to known antiviral inhibitors of HPIV-3, the rHPIV3-EGFP virus was
more susceptible to inhibition than HPIV-3 WT, which led to reductions in EC50 values.
This may be due to the additional resources and time necessary to express the foreign
EGFP gene from the viral genome, which slows viral RNA synthesis and attenuating the
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virus. Ultimately, if the rHPIV3-EGFP virus were to be used in antiviral assays, lower
EC50 values might be obtained that would raise SI values and could increase the number
of false-positive antiviral compounds passing the initial round of screening. In the realm
of high-throughput antiviral screening though, this consequence is acceptable because
during the second round of antiviral compound screening the HPIV-3 WT virus would be
used and false-positive compounds would be eliminated from further examination. In
fact, when the rHPIV3-EGFP virus was tested against a panel of known HPIV-3
inhibitors in MA-104 cells a decrease in EC50 values was generally detected. The
decrease in EC50 values ultimately increased the SI values for identical antiviral
compounds when measuring viral replication by EGFP fluorescence compared to the
traditional NR dye uptake assay.
In addition, the replication of the rHPIV3-ΔES and rHPIV3-ΔD knockout viruses
in the more restrictive, IFN-β expressing A549 cell line were also attenuated, which may
suggest that the D domain may perturb the host cell’s antiviral response, in addition to
influencing viral RNA synthesis. But, taking into account that both rHPIV3-ΔES and
rHPIV3-ΔD knockout viruses were attenuated in both the non-IFN-β expressing MA-104
and IFN-β expressing A549 cells, heavily favors the theory that the D domain plays a role
in viral RNA synthesis and not in disrupting the host cell’s antiviral response. Also, a
reduction or no change in cytokine expression levels was detected in A549 cells infected
with either knockout virus compared to the rHPIV3-NT parent virus. This result further
supports the idea that the D domain may be involved in viral RNA synthesis rather than
disrupting the host cell’s antiviral response.

On the other hand, when the rHPIV3-ΔES knockout virus was used to infect
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A549 cells, a full-log reduction in viral titers was detected compared to a 50% viral titer
reduction of the same virus in MA-104 cells. Also, the expression of the IFN-β and
RANTES cytokines from A549 cells infected with the rHPIV3-ΔES knockout virus were
increased compared to the identical cytokines expressed from A549 cells infected with
rHPIV3-ΔD. These data suggests that the six amino acids, which make up a portion of a
nuclear localization signal, removed from the rHPIV3-ΔES, virus may play an additional
luxury role in disrupting the A549 cell’s antiviral response.
In conclusion, the similar methods used in reverse genetics have allowed the
investigation of two different hypotheses involving the HPIV-3 virus. The first
hypothesis was found to be incorrect in that the insertion of a foreign gene into the viral
genome to be expressed as an additional gene did attenuate the virus. But along with
further evaluation, it was concluded that the attenuation of the rHPIV3-EGFP virus was
acceptable and the rHPIV3-EGFP virus could be used as a suitable replacement for the
HPIV-3 WT virus in antiviral assays. To improve the assay, further research is needed to
find a non-green fluorescent dye to measure cell toxicity induced by the antiviral
compounds. If one were found, compound cellular toxicity and effectiveness against the
HPIV-3 virus could be measured in the same cell culture well and perhaps scaled up to
384-well plates for high-throughput screening.
The second hypothesis was also found to be false in that the D domain expressed
from the P gene of HPIV-3 may be involved with viral RNA synthesis rather than
disrupting the host cell’s antiviral response. Knowing that the PD protein, whose
C-terminal end is the D domain, translocates to the cellular nucleus and that cellular
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mRNA transcription and cellular genomic replication occur there, the PD protein might
recruit cellular nuclear proteins or cofactors that assist in viral RNA synthesis. Further
research is needed to determine exactly what cellular and/or viral proteins the PD protein
interacts with and what the purpose of the PD protein in the cellular nucleus is. Also,
additional research is needed to further investigate the exact function of the nuclear
localization signal present on the N-terminal end of the HPIV-3 P, PD, and W proteins.
It seems that the signal may be involved in some aspect that disrupts the host cell’s
antiviral response rather than influencing viral RNA synthesis. Perhaps once inside the
nucleus, the N-terminal end of the P, PD, and W proteins directly interferes with IFN-β
expression.
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APPENDIX A
TIME COURSE OF IFN-Β EXPRESSED FROM A549 AND MA-104
CELLS INFECTED WITH RHPIV3-NT

Introduction
Gao et al. (1999) determined that an HPIV-3 infection of A549 cells induced
IFN-β, although peak expression of IFN-β during an infection was not shown in that
study. In addition, no research could be found that reported the expression of IFN-β from
MA-104 cells infected with any virus. The current study was undertaken to determine
when the expression of IFN-β from A549 cells, infected with the rHPIV3-NT parent
virus, was maximal during the course of the infection. In addition, the expression levels
of IFN-β from MA-104 cells infected with rHPIV3-NT was also determined.
Materials and Methods
Two 24-well plates were seeded with A549 and MA-104 cells and infected with
the rHPIV3-NT viruses at an MOI = 0.1 (3.7 x 104 PFU for A549 cells and 2.5 x 104 PFU
for MA-104 cells). The virus was absorbed for 2 h at 37°C. The virus inocula were
removed, replaced with fresh MEM supplemented with 2% FBS, and incubated at 37°C
for 16-32 h. Every 4 h, starting at 16 h and ending at 32 h post virus infection, the tissue
culture medium for the infected and uninfected wells was removed and stored at -80°C.
Fresh MEM was added to the infected and uninfected tissue culture wells and incubated
for another 4 h. Cytokine levels present in the tissue culture media were measured by
ELISA using the VeriKine™ Human Interferon-Beta ELISA Kit (PBL InterferonSource)
to measure IFN-β levels secreted by A549 and MA-104 cells. The level of detection of

IFN-β for the kit is 25-2000 pg/mL. The assay was measured on a SpectraMax Plus
®
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384

spectrophotometer (wavelength 450 nm) and the data was analyzed with SOFTmax®
PRO software.

Results
As expected, expression of IFN-β from A549 cells infected with rHPIV3-NT
increased dramatically over time compared to mock infected A549 cell controls. Peak
expression of IFN-β occurred at 24 h post infection (Fig. A-1). In contrast, infected
MA-104 cells expressed levels of IFN-β below detectable limits of the assay during the
rHPIV3-NT infection similar to mock infected MA-104 cell controls.
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0
0

8

16

24

32
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Fig. A-1. Time course of IFN-β expression from A549 and MA-104 cells infected with
rHPIV3-NT. IFN-β expression from infected A549 cells (♦), mock infected A549 cells
(■), infected MA-104 cells (▲), and mock infected MA-104 cells (●) measured by
ELISA. Y-axis values for infected cells represent the mean ± S.D. of duplicate assays.
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Conclusions
Since peak expression of IFN-β occurred at 24 h post infection, IFN-β and other
cytokine expression levels were measured at this time point (Fig. 4-4). The fact that
MA-104 cells do not express IFN-β might explain why MA-104 cells are more
susceptible to HPIV-3 infections, which result in 100% CPE.

Reference
Gao, J., De, B.P., Banerjee, A.K., 1999. Human parainfluenza virus type 3 up-regulates
major histocompatibility complex class I and II expression on respiratory
epithelial cells: involvement of a STAT1- and CIITA-independent pathway. J.
Virol. 73, 1411-1418.
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APPENDIX B
SCREENING OF A CDNA LIBRARY AMPLIFIED FROM THE P
GENE IN AN HPIV-3 WT INFECTION

Introduction
Galinski et al. (1992) identified an RNA editing site in the P gene of HPIV-3 at
nucleotide position 791–805. They reported that the viral polymerase stops and stutters
at this particular location adding 1–12 G residues indiscriminately when they screened a
pool of approximately 50 clones. They also reported no insertion of additional G
residues at a second possible editing site, nucleotide position 1121–1136. The current
study was undertaken to confirm the insertion of non-templated G residues at nucleotide
position 791–805 and to identify any other possible editing sites downstream of the
known editing site to nucleotide position 1519 in the P gene using modern techniques.

Materials and Methods
MA-104 cells were seeded in 12-well plates and infected with HPIV-3 WT at an
MOI = 0.1 (3 x 104 PFU). The virus was absorbed for 2 h at 37°C. The virus inoculum
was removed, replaced with fresh MEM supplemented with 2% FBS, and incubated at
37°C for 2 days. Total RNA, cellular and viral, was isolated from the infected MA-104
cells using the RNeasy® Plus Mini Kit (Qiagen). A cDNA library was constructed by
converting all mRNA into cDNA using the SuperScript® III First-Strand Synthesis
SuperMix (Invitrogen) and the Oligo(dT)20 primer supplied in the kit. HPIV-3 P gene
mRNA was amplified by PCR using the AccuPrime™ Pfx SuperMix (Invitrogen), the
forward primer, 5’-TCTTCAACACATCAAGAAGATGACAA-3’, and the
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5’-GTGCCTCCATAAGTGGGTCAAAC-3’ reverse primer. The PCR products were
inserted into the SmaI site of pUC19 and transformed into electrocompetent cells.
Plasmid DNA was isolated from total of 105 clones and sequenced.

Results
The unedited P gene (+0G) was the most prevalent mRNA species detected in the
P gene cDNA library, which represented 60% of the total clones screened (Table A-1).
The other mRNA species found in the cDNA library had between 1 and 5 non-templated
G residues added with rates ranging from 4.8% to 13.3% of the total clones screened.
Accounting for the fact that 3 nt equals 1 amino acid, the mRNA species can be
combined into groups that express the same protein. The mRNA species with +0 and +3
G insertions account for 67.6% of the mRNA transcripts and express the P protein (Table
A-1). The mRNA species with +1 and +4 G insertions account for 18.1% of the mRNA

Table A-1
Amplitude of non-templated G residue insertion during RNA editing in the P gene of the
HPIV-3 WT virus.
Unedited
+0

Number of Non-templated G Residues Added
+1
+2
+3
+4
+5

Total
105

Number of
Clones

63

14

7

8

5

8

Percentage of
Clones

60.0%

13.3%

6.7%

7.6%

4.8%

7.6%

P protein
(+0 and +3 G)

W protein
(+1 and +4 G)

PD protein
(+2 and +5 G)

Number of
Clones

71

19

15

Percentage of
Clones

67.6%

18.1%

14.3%

105
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transcripts and express the W protein. The mRNA species with +2 and +5 G insertions
account for 14.3% of the mRNA transcripts and express the PD protein. In addition, the
alignments of all 105 cDNA clones did not exhibit any other editing sites between
nucleotides 699–1519, which would have been seen by the insertion of additional nontemplated nucleotides (Fig. A-2).

Conclusions
Although, Galinski et al. (1992) reported the insertion of 1–12 non-templated G
residues that the HPIV-3 viral polymerase adds at the editing site of the P gene, the
current study found the insertion of only 1–5 non-templated G residues in the editing site.
However, this study confirmed that the amplitude of insertions does occur
indiscriminately, even though +1 G was slightly favored. In addition, no other nucleotide
insertions or editing sites in the P gene within nucleotide position 699–1519 were found.

Reference
Galinski, M.S., Troy, R.M., Banerjee, A.K., 1992. RNA editing in the phosphoprotein
gene of the human parainfluenza virus type 3. Virology 186, 543-550.

137
+0G
+1G
+2G
+3G
+4G
+5G

1
1
1
1
1
1

AGATGACAAAAGAATTAAAAAAGGGGG-----AAAAGGGAAAGACTGGTTTAAGAAATCA
AGATGACAAAAGAATTAAAAAAGGGGGG----AAAAGGGAAAGACTGGTTTAAGAAATCA
AGATGACAAAAGAATTAAAAAAGGGGGGG---AAAAGGGAAAGACTGGTTTAAGAAATCA
AGATGACAAAAGAATTAAAAAAGGGGGGGG--AAAAGGGAAAGACTGGTTTAAGAAATCA
AGATGACAAAAGAATTAAAAAAGGGGGGGGG-AAAAGGGAAAGACTGGTTTAAGAAATCA
AGATGACAAAAGAATTAAAAAAGGGGGGGGGGAAAAGGGAAAGACTGGTTTAAGAAATCA

+0G
+1G
+2G
+3G
+4G
+5G

56
57
58
59
60
61

55AAAGATACTGACAACCAGATACCAACATCAGACTACAGATCCACATCAAAAGGGCAG
56AAAGATACTGACAACCAGATACCAACATCAGACTACAGATCCACATCAAAAGGGCAG
57AAAGATACTGACAACCAGATACCAACATCAGACTACAGATCCACATCAAAAGGGCAG
58AAAGATACTGACAACCAGATACCAACATCAGACTACAGATCCACATCAAAAGGGCAG
59AAAGATACTGACAACCAGATACCAACATCAGACTACAGATCCACATCAAAAGGGCAG
60AAAGATACTGACAACCAGATACCAACATCAGACTACAGATCCACATCAAAAGGGCAG

+0G
+1G
+2G
+3G
+4G
+5G

113
114
115
116
117
118

AAG
AAG
AAG
AAG
AAG
AAG

+0G
+1G
+2G
+3G
+4G
+5G

169
170
171
172
173
174

ACAGACA
ACAGACA
ACAGACA
ACAGACA
ACAGACA
ACAGACA

+0G
+1G
+2G
+3G
+4G
+5G

225
226
227
228
229
230

ACACCGACCGA
ACACCGACCGA
ACACCGACCGA
ACACCGACCGA
ACACCGACCGA
ACACCGACCGA

+0G
+1G
+2G
+3G
+4G
+5G

281
282
283
284
285
286

ACCTATACAAAAGAA
ACCTATACAAAAGAA
ACCTATACAAAAGAA
ACCTATACAAAAGAA
ACCTATACAAAAGAA
ACCTATACAAAAGAA

115AAAATCTCAAAGACAACAACCATCAACACCGACACAAAGGGGCAAACAGAAAT
116AAAATCTCAAAGACAACAACCATCAACACCGACACAAAGGGGCAAACAGAAAT
117AAAATCTCAAAGACAACAACCATCAACACCGACACAAAGGGGCAAACAGAAAT
118AAAATCTCAAAGACAACAACCATCAACACCGACACAAAGGGGCAAACAGAAAT
119AAAATCTCAAAGACAACAACCATCAACACCGACACAAAGGGGCAAACAGAAAT
120AAAATCTCAAAGACAACAACCATCAACACCGACACAAAGGGGCAAACAGAAAT

175GAATCATCAGAAACACAATCTTCATCATGGAATCTCATCATCGACAACA
176GAATCATCAGAAACACAATCTTCATCATGGAATCTCATCATCGACAACA
177GAATCATCAGAAACACAATCTTCATCATGGAATCTCATCATCGACAACA
178GAATCATCAGAAACACAATCTTCATCATGGAATCTCATCATCGACAACA
179GAATCATCAGAAACACAATCTTCATCATGGAATCTCATCATCGACAACA
180GAATCATCAGAAACACAATCTTCATCATGGAATCTCATCATCGACAACA

235AACGAACAGACAAGCACAACTCCTCCAACAACAACTTCAAGATCA
236AACGAACAGACAAGCACAACTCCTCCAACAACAACTTCAAGATCA
237AACGAACAGACAAGCACAACTCCTCCAACAACAACTTCAAGATCA
238AACGAACAGACAAGCACAACTCCTCCAACAACAACTTCAAGATCA
239AACGAACAGACAAGCACAACTCCTCCAACAACAACTTCAAGATCA
240AACGAACAGACAAGCACAACTCCTCCAACAACAACTTCAAGATCA

295TCGATCCGAACAAACTCTGAATCCAAACCCAAGACACAAAA
296TCGATCCGAACAAACTCTGAATCCAAACCCAAGACACAAAA
297TCGATCCGAACAAACTCTGAATCCAAACCCAAGACACAAAA
298TCGATCCGAACAAACTCTGAATCCAAACCCAAGACACAAAA
299TCGATCCGAACAAACTCTGAATCCAAACCCAAGACACAAAA
300TCGATCCGAACAAACTCTGAATCCAAACCCAAGACACAAAA

Fig. A-2. Alignment of selected cDNA library clones showing unedited (+0G) and
non-templated G insertions (+1G–+5G). The alignment does not indicate any other
nucleotide insertions or editing sites downstream of the main editing site to nucleotide
position 1519.
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+0G
+1G
+2G
+3G
+4G
+5G

337
338
339
340
341
342

GACAAATGGAAAGGAAAGG
GACAAATGGAAAGGAAAGG
GACAAATGGAAAGGAAAGG
GACAAATGGAAAGGAAAGG
GACAAATGGAAAGGAAAGG
GACAAATGGAAAGGAAAGG

+0G
+1G
+2G
+3G
+4G
+5G

393
394
395
396
397
398

CAATTACTCTATTGCAGAATCTT
CAATTACTCTATTGCAGAATCTT
CAATTACTCTATTGCAGAATCTT
CAATTACTCTATTGCAGAATCTT
CAATTACTCTATTGCAGAATCTT
CAATTACTCTATTGCAGAATCTT

+0G
+1G
+2G
+3G
+4G
+5G

449
450
451
452
453
454

TATCAAGACAAACGAGTTGTATGTGTA
TATCAAGACAAACGAGTTGTATGTGTA
TATCAAGACAAACGAGTTGTATGTGTA
TATCAAGACAAACGAGTTGTATGTGTA
TATCAAGACAAACGAGTTGTATGTGTA
TATCAAGACAAACGAGTTGTATGTGTA

+0G
+1G
+2G
+3G
+4G
+5G

505
506
507
508
509
510

ATCAAAGATAGACTTCCTGGCAGGATTAGTC
ATCAAAGATAGACTTCCTGGCAGGATTAGTC
ATCAAAGATAGACTTCCTGGCAGGATTAGTC
ATCAAAGATAGACTTCCTGGCAGGATTAGTC
ATCAAAGATAGACTTCCTGGCAGGATTAGTC
ATCAAAGATAGACTTCCTGGCAGGATTAGTC

+0G
+1G
+2G
+3G
+4G
+5G

561
562
563
564
565
566

CAAAATTAACACAGATACAAAATGAAATGCTAAAC
CAAAATTAACACAGATACAAAATGAAATGCTAAAC
CAAAATTAACACAGATACAAAATGAAATGCTAAAC
CAAAATTAACACAGATACAAAATGAAATGCTAAAC
CAAAATTAACACAGATACAAAATGAAATGCTAAAC
CAAAATTAACACAGATACAAAATGAAATGCTAAAC

+0G
+1G
+2G
+3G
+4G
+5G

617
618
619
620
621
622

ATGGACGAATCACATAGAAGATTGATAGAAAATCAAAGA
ATGGACGAATCACATAGAAGATTGATAGAAAATCAAAGA
ATGGACGAATCACATAGAAGATTGATAGAAAATCAAAGA
ATGGACGAATCACATAGAAGATTGATAGAAAATCAAAGA
ATGGACGAATCACATAGAAGATTGATAGAAAATCAAAGA
ATGGACGAATCACATAGAAGATTGATAGAAAATCAAAGA

Fig. A-2. Continued

355AAGGATACAGAAGAGAGCAATCGATTTACAGAGAGGG
356AAGGATACAGAAGAGAGCAATCGATTTACAGAGAGGG
357AAGGATACAGAAGAGAGCAATCGATTTACAGAGAGGG
358AAGGATACAGAAGAGAGCAATCGATTTACAGAGAGGG
359AAGGATACAGAAGAGAGCAATCGATTTACAGAGAGGG
360AAGGATACAGAAGAGAGCAATCGATTTACAGAGAGGG

415GGTGTAATCCAATCTACATCAAAATTAGATTTA
416GGTGTAATCCAATCTACATCAAAATTAGATTTA
417GGTGTAATCCAATCTACATCAAAATTAGATTTA
418GGTGTAATCCAATCTACATCAAAATTAGATTTA
419GGTGTAATCCAATCTACATCAAAATTAGATTTA
420GGTGTAATCCAATCTACATCAAAATTAGATTTA

475GCAAATGTACTAAACAATGTAGATACTGC
476GCAAATGTACTAAACAATGTAGATACTGC
477GCAAATGTACTAAACAATGTAGATACTGC
478GCAAATGTACTAAACAATGTAGATACTGC
479GCAAATGTACTAAACAATGTAGATACTGC
480GCAAATGTACTAAACAATGTAGATACTGC

535ATAGGGGTTTCAATGGATAACGACA
536ATAGGGGTTTCAATGGATAACGACA
537ATAGGGGTTTCAATGGATAACGACA
538ATAGGGGTTTCAATGGATAACGACA
539ATAGGGGTTTCAATGGATAACGACA
540ATAGGGGTTTCAATGGATAACGACA

595CTCAAAACAGATCTAAAGAAA
596CTCAAAACAGATCTAAAGAAA
597CTCAAAACAGATCTAAAGAAA
598CTCAAAACAGATCTAAAGAAA
599CTCAAAACAGATCTAAAGAAA
600CTCAAAACAGATCTAAAGAAA

655GAACAACTGTCATTGAT
656GAACAACTGTCATTGAT
657GAACAACTGTCATTGAT
658GAACAACTGTCATTGAT
659GAACAACTGTCATTGAT
660GAACAACTGTCATTGAT
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+0G
+1G
+2G
+3G
+4G
+5G

673
674
675
676
677
678

CACGTCATTAATTTCAAATCTTAAAATTATGACTGAGAGAGGA
CACGTCATTAATTTCAAATCTTAAAATTATGACTGAGAGAGGA
CACGTCATTAATTTCAAATCTTAAAATTATGACTGAGAGAGGA
CACGTCATTAATTTCAAATCTTAAAATTATGACTGAGAGAGGA
CACGTCATTAATTTCAAATCTTAAAATTATGACTGAGAGAGGA
CACGTCATTAATTTCAAATCTTAAAATTATGACTGAGAGAGGA

+0G
+1G
+2G
+3G
+4G
+5G

729
730
731
732
733
734

AAAATGAATCCACTGAGAGAGTATCCATGATCAAAACAAAATTGAAA
AAAATGAATCCACTGAGAGAGTATCCATGATCAAAACAAAATTGAAA
AAAATGAATCCACTGAGAGAGTATCCATGATCAAAACAAAATTGAAA
AAAATGAATCCACTGAGAGAGTATCCATGATCAAAACAAAATTGAAA
AAAATGAATCCACTGAGAGAGTATCCATGATCAAAACAAAATTGAAA
AAAATGAATCCACTGAGAGAGTATCCATGATCAAAACAAAATTGAAA

+0G
+1G
+2G
+3G
+4G
+5G

785
786
787
788
789
790

ATCAAGAAGACCAGGTTTGACCCACTTATGGAGGCAC
ATCAAGAAGACCAGGTTTGACCCACTTATGGAGGCAC
ATCAAGAAGACCAGGTTTGACCCACTTATGGAGGCAC
ATCAAGAAGACCAGGTTTGACCCACTTATGGAGGCAC
ATCAAGAAGACCAGGTTTGACCCACTTATGGAGGCAC
ATCAAGAAGACCAGGTTTGACCCACTTATGGAGGCAC
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715GGTAAGAAAGACC
716GGTAAGAAAGACC
717GGTAAGAAAGACC
718GGTAAGAAAGACC
719GGTAAGAAAGACC
720GGTAAGAAAGACC

775GAAGAAAAG
776GAAGAAAAG
777GAAGAAAAG
778GAAGAAAAG
779GAAGAAAAG
780GAAGAAAAG
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